In re: Entresto (Sacubitril/Valsartan) Patent Litigation
Defendant: Noratech Labs, Inc.
Counter Claimant: Biocon Pharma Limited, Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Lupin Inc., Macleods Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Inc., Crystal Pharmaceutical (Suzhou) Co., Ltd., Lupin Atlantis Holdings, S.A., Alembic Pharmaceuticals Limited, Macleods Pharma USA, Inc., Laurus Labs Limited, Aurobindo Pharma USA Inc., Lupin Pharmaceuticals, Inc., Dr. Reddys Laboratories, Ltd. and Biocon Limited
Not Classified By Court: Hetero USA Inc.,, Torrent Pharma Inc., Zydus Pharmaceuticals (USA) Inc., Torrent Pharmaceuticals Ltd., Novugen Pharma (Malaysia) Sdn. Bhd., Hetero Labs Limited Unit III, Nanjing Noratech Pharmaceutical Co., Limited, Laurus Generics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, Lupin Limited, MSN Pharmaceuticals Inc., Alembic Pharmaceuticals, Inc., Hetero Labs Limited, Cadila Healthcare Ltd., Clerk of MDL Panel and Mylan Pharmaceuticals Inc.
In Re: Entresto (Sacubitril/Valsartan) Patent Litigation
Counter Defendant: Novartis Pharmaceuticals Corporation
Case Number: 1:2020md02930
Filed: March 27, 2020
Court: US District Court for the District of Delaware
Presiding Judge: Richard G Andrews
Referring Judge: Leonard P Stark
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA)
Cause of Action: 35 U.S.C. § 271 Patent Infringement
Jury Demanded By: None
RSS RSS Track this Docket
Docket Report

This docket was last retrieved on April 4, 2022. A more recent docket listing may be available from PACER.

Date Filed Document Text
April 4, 2022 Filing 535 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth)
April 4, 2022 Filing 534 ANSWER to Complaint as filed in C.A. No. 22-32, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Alkem Laboratories Ltd..(Dorsney, Kenneth)
April 4, 2022 Filing 533 NOTICE of Appearance by John C. Phillips, Jr on behalf of Nanjing Noratech Pharmaceutical Co., Limited (Phillips, John)
April 4, 2022 Filing 532 NOTICE OF SERVICE of Reply Expert Report of Ivan T. Hofmann filed by Laurus Generics Inc., Laurus Labs Limited.(Poff, Adam)
April 4, 2022 Filing 531 MOTION for Pro Hac Vice Appearance of Attorney Lina Genovesi - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Dorsney, Kenneth)
April 4, 2022 Opinion or Order ORAL ORDER: A Status/Scheduling Conference is now set for 4/20/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 4/4/2022. (nms)
April 4, 2022 Opinion or Order SO ORDERED, re (D.I. 531 in 20-md-2930-RGA; D.I. 418 in 19-cv-1979-RGA) MOTION for Pro Hac Vice Appearance of Attorney Lina Genovesi, filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. Signed by Judge Richard G. Andrews on 4/4/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA(nms)
April 1, 2022 Filing 530 NOTICE OF SERVICE of Reply Expert Report of Dr. Laird Forrest Regarding Invalidity of U.S. Patent Nos. 8,101,659 and 8,796,331 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
April 1, 2022 Filing 529 NOTICE OF SERVICE of Reply Expert Report of Dr. Alexander M. Klibanov on Infringement by Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
April 1, 2022 Filing 528 NOTICE OF SERVICE of the Reply Expert Report of Dan Fintel, M.D., on the Invalidity of the '659 and '331 Patents filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc..(Ormerod, Eve)
April 1, 2022 Filing 527 NOTICE OF SERVICE of Reply Expert Report of Dr. Jonathan W. Steed filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
March 31, 2022 Opinion or Order Filing 526 [SEALED] ORDER Granting (D.I. 524 in 20-md-2930-RGA; D.I. 233 in 19-cv-2053-RGA) Stipulation and Proposed Order Regarding Defendant MSN's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331. Signed by Judge Richard G. Andrews on 3/31/2022.*This order has been emailed to local counsel. Associated Cases: 1:19-cv-02053-RGA, 1:20-md-02930-RGA(nms)
March 31, 2022 Opinion or Order Filing 525 [SEALED] ORDER Granting (D.I. 523 in 20-md-2930-RGA; D.I. 412 in 19-cv-1979-RGA) Stipulation and Proposed Order Dismissing Novartis's '938 and '134 Patent Claims Against Biocon and Biocon's Counterclaims Against the '938 and '134 Patents. Signed by Judge Richard G. Andrews on 3/31/2022.*This order has been emailed to local counsel. Associated Cases: 1:19-cv-01979-RGA, 1:20-md-02930-RGA(nms)
March 31, 2022 Filing 524 [SEALED] STIPULATION and [Proposed] Order Regarding Defendant MSN's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331 by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
March 31, 2022 Filing 523 [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Biocon and Biocon's Counterclaims Against the '938 and '134 Patents by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
March 29, 2022 Filing 522 REDACTED VERSION of #516 Stipulation, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 3/29/2022 (nms).
March 28, 2022 Opinion or Order SO ORDERED, re (D.I. 169 in 20-cv-445-RGA; D.I. 520 in 20-md-2930-RGA: D.I. 410 in 19-cv-1979-RGA; D.I. 232 in 19-cv-2053-RGA) STIPULATION TO EXTEND TIME to serve reply expert reports concerning infringement to April 7, 2022. Signed by Judge Richard G. Andrews on 3/28/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms)
March 25, 2022 Filing 521 REDACTED VERSION of #510 Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/28/2022 (nms).
March 25, 2022 Filing 520 STIPULATION and Proposed Order to Extend Time to serve reply expert reports concerning infringement to April 7, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/28/2022 (nms).
March 24, 2022 Opinion or Order Filing 519 [SEALED] ORDER Granting (D.I. 516 in 20-md-2930-RGA; D.I. 123 in 20-cv-74-RGA; D.I. 153 in 19-cv-2021-RGA) Stipulation and [Proposed] Order Staying Litigation with Respect to Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.. Signed by Judge Richard G. Andrews on 3/24/2022.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA, 1:20-cv-00074-RGA(nms)
March 23, 2022 Filing 518 REDACTED VERSION of #399 Declaration, by Noratech Labs, Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F)(Haney, Megan) Modified on 3/24/2022 (nms).
March 23, 2022 Filing 517 REDACTED VERSION of #506 Reply Brief, by Noratech Labs, Inc.. (Haney, Megan) Modified on 3/24/2022 (nms).
March 23, 2022 Filing 516 [SEALED] STIPULATION and [Proposed] Order Staying Litigation with Respect to Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
March 21, 2022 Filing 515 JOINT Status Report, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 3/22/2022 (nms).
March 16, 2022 Filing 514 STIPULATION and Proposed Order - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Haney, Megan) Modified on 3/16/2022 (nms).
March 16, 2022 Opinion or Order Filing 513 ORAL ORDER: The parties to the MDL and its member cases are to file a joint status report no later than three (3) days from the date of this Order. Specifically the parties should address (1) scheduled deadlines and events currently in place, (2) matters that are outstanding and need Court attention, and (3) for the cases related to the MDL but not member cases of the MDL, what the relationship is, including in particular what overlap (for example, the same patents, different patents but the same patent family, the same branded products, the same generic products) the related cases have with the member cases. Ordered by Judge Richard G. Andrews on 3/16/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms)
March 16, 2022 Opinion or Order Filing 512 [SEALED] ORDER Granting (D.I. 402 in 19-cv-1979-RGA D.I. 510 in 20-md-2930-RGA) Stipulation and Proposed Order Regarding Defendant Alkem's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331. Signed by Judge Richard G. Andrews on 3/16/2022.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA(nms)
March 16, 2022 Opinion or Order SO ORDERED, Granting (D.I. 406 in 19-cv-1979-RGA; D.I. 514 in 20-md-2930-RGA) STIPULATION and Proposed Order extending time to submit redacted filings to March 23, 2022. Signed by Judge Richard G. Andrews on 3/16/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA(nms)
March 15, 2022 Opinion or Order Filing 511 ORDER in MDL No. 2930 Reassigning Litigation to Judge Richard G. Andrews. Signed by Karen K. Caldwell, Chair on 3/15/22. Associated Cases: 1:20-md-02930-LPS et al. (ntl)
March 15, 2022 Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00074-RGA and 1:20-cv-00445-RGA (rjb)
March 14, 2022 Filing 510 [SEALED] STIPULATION and [Proposed] Order Regarding Defendant Alkem's Infingement of U.S. Patent Nos. 8,101,659 and 8,796,331 by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
March 10, 2022 Filing 509 Amended Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd., Other Affiliate Capital Research Global Investors for Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc. filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan)
March 10, 2022 Filing 508 REQUEST for Oral Argument by Nanjing Noratech Pharmaceutical Co., Limited re (472 in 1:20-md-02930-LPS, 370 in 1:19-cv-01979-LPS) MOTION for Attorney Fees Pursuant to 35 U.S.C. 285. (Phillips, John)
March 9, 2022 Filing 507 [SEALED] DECLARATION of Don J. Mizerk re #472 MOTION for Attorney Fees Pursuant to 35 U.S.C. 285, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F)(Phillips, John) Modified on 3/16/2022 (nms).
March 9, 2022 Filing 506 [SEALED] REPLY BRIEF re #472 MOTION for Attorney Fees Pursuant to 35 U.S.C. 285, filed by Nanjing Noratech Pharmaceutical Co., Limited. (Phillips, John) Modified on 3/16/2022 (nms).
March 7, 2022 Filing 505 REDACTED VERSION of #502 Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/16/2022 (nms).
March 2, 2022 Filing 504 REDACTED VERSION of #495 Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/16/2022 (nms).
March 2, 2022 Filing 503 REDACTED VERSION of #494 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/16/2022 (nms).
March 1, 2022 Opinion or Order SO ORDERED, re (394 in 19-cv-1979-LPS; 502 in 20-md-2930-LPS) [SEALED] STIPULATION and [Proposed] Order Regarding Defendant Aurobindo's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331. Signed by Judge Leonard P. Stark on 2/28/22. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS (ntl) Modified on 3/16/2022 (nms).
February 28, 2022 Filing 502 [SEALED] STIPULATION and [Proposed] Order Regarding Defendant Aurobindo's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331 by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
February 25, 2022 Opinion or Order Filing 501 SO ORDERED, re (499 in 1:20-md-02930-LPS, 391 in 1:19-cv-01979-LPS) STIPULATION TO EXTEND TIME the deadline to file public redacted versions of (1) Novartis's Answering Brief in Opposition to Noratech's Motion for Fees Pursuant to 35 U.S.C. 285 (C.A. 20-md-2930, D.I. 494 / C.A. 19-1979, D.I. 387), and filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/25/2022. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS(etg)
February 25, 2022 Opinion or Order SO ORDERED, re (498 in 1:20-md-02930-LPS, 390 in 1:19-cv-01979-LPS) STIPULATION TO EXTEND TIME for Noratech to file its Reply Brief in Support of its Motion for Fees to March 9, 2022 filed by Nanjing Noratech Pharmaceutical Co., Limited. Signed by Judge Leonard P. Stark on 2/25/2022. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS(etg)
February 23, 2022 Filing 500 REDACTED VERSION of #492 Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/16/2022 (nms).
February 23, 2022 Filing 499 STIPULATION TO EXTEND TIME the deadline to file public redacted versions to March 2, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/16/2022 (nms).
February 22, 2022 Filing 498 STIPULATION TO EXTEND TIME for Noratech to file its Reply Brief in Support of its Motion for Fees to March 9, 2022 - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Haney, Megan)
February 22, 2022 Filing 497 REDACTED VERSION of (384 in 1:19-cv-01979-LPS, 491 in 1:20-md-02930-LPS) Stipulation, and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims against Aurobindo and Aurobindo's Counterclaims Against the '938 and '134 Patents by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
February 18, 2022 Opinion or Order SO ORDERED, re (492 in 1:20-md-02930-LPS, 385 in 1:19-cv-01979-LPS) [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Laurus and Laurus's Counterclaims Against the '938, '134, '390, and '744 Patents. Signed by Judge Leonard P. Stark on 2/17/22. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
February 18, 2022 Opinion or Order SO ORDERED, re (384 in 1:19-cv-01979-LPS, 491 in 1:20-md-02930-LPS) [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Aurobindo and Aurobindo's Counterclaims Against the '938 and '134 Patents. Signed by Judge Leonard P. Stark on 2/17/22. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
February 17, 2022 Filing 496 NOTICE OF SERVICE of Responsive Expert Report of Mark Hollingsworth Regarding Noninfringement of U.S. Patent No. 8,877,938 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
February 16, 2022 Filing 495 [SEALED] DECLARATION re (494 in 1:20-md-02930-LPS) Answering Brief in Opposition, (387 in 1:19-cv-01979-LPS) Answering Brief in Opposition, of Jared L. Stringham, Esq. by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-25 Pt. 1 of 3, #2 Exhibit 1-25 Pt. 2 of 3, #3 Exhibit 1-25 pt. 3 of 3, #4 Certificate of Service)(Silver, Daniel)
February 16, 2022 Filing 494 [SEALED] ANSWERING BRIEF in Opposition re #472 MOTION for Attorney Fees Pursuant to 35 U.S.C. 285 filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 2/23/2022. (Attachments: #1 Certificate of Service)(Silver, Daniel)
February 16, 2022 CORRECTING ENTRY: Corrected document (further redacted) added to D.I. 493 in 20md2930, D.I. 386 in 19-1979, D.I. 122 in 20-415, and D.I. 40 in 21-229 per request of counsel. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:20-cv-00415-LPS, 1:21-cv-00229-LPS (ntl)
February 14, 2022 Filing 493 REDACTED VERSION of (119 in 1:20-cv-00415-LPS, 376 in 1:19-cv-01979-LPS, 481 in 1:20-md-02930-LPS, 39 in 1:21-cv-00229-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Main Document 493 replaced on 2/16/2022) (ntl).
February 14, 2022 Filing 492 [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Laurus and Laurus's Counterclaims Against the '938, '134, '390, and '744 Patents by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
February 14, 2022 Filing 491 [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Aurobindo and Aurobindo's Counterclaims Against the '938 and '134 Patents by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
February 11, 2022 Filing 490 NOTICE OF SERVICE of Responsive Expert Report of Bernhardt L. Trout, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
February 11, 2022 Filing 489 NOTICE OF SERVICE of Rebuttal Expert Report of Marek Zakrzewski, Ph.D. on Non-Infringement of the '938 and '134 Patents for Teva Pharmaceuticals USA, Inc. filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
February 11, 2022 Filing 488 MOTION for Pro Hac Vice Appearance of Attorney Jeanna M. Wacker - filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan)
February 11, 2022 Filing 487 NOTICE requesting Clerk to remove Mira Mulvaney as co-counsel.. (Hoeschen, Nathan)
February 11, 2022 Filing 486 NOTICE OF SERVICE of (1) Responsive Expert Report of Francis G. Spinale, MD, PHD Regarding Validity of the 659 and 331 Patents; (2) Responsive Expert Report of Dr. Alexander M. Klibanov on the Validity of the 659 and 331 Patents; and (3) Expert Report of Gregory K. Bell, PH.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
February 11, 2022 Filing 485 NOTICE OF SERVICE of Rebuttal Expert Report of Dr. Tomislav Friscic [Highly Confidential-Attorneys' Eyes Only] and Declaration of Dr. Hatem Titi [Highly Confidential-Attorneys' Eyes Only] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
February 11, 2022 Pro Hac Vice Attorney Jeanna M. Wacker for Teva Pharmaceuticals USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk)
February 11, 2022 Opinion or Order SO ORDERED, re (381 in 1:19-cv-01979-LPS, 488 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Jeanna M. Wacker filed by Teva Pharmaceuticals USA, Inc. Signed by Judge Leonard P. Stark on 2/11/22. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
February 10, 2022 Filing 484 NOTICE OF SERVICE of Responsive Expert Report of Mark D. Hollingsworth Regarding Noninfringement of U.S. Patent No. 8,101,659 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios)
February 9, 2022 Opinion or Order SO ORDERED, re #481 Stipulation of Dismissal filed by Novartis Pharmaceuticals Corporation -- Party Lupin Inc., Lupin Inc., Lupin Limited, Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Lupin Atlantis Holdings, S.A. and Lupin Atlantis Holdings, S.A. terminated. Attorney Alexandra M. Ewing; Carol M. Pitzel Cruz; William R. Zimmerman; Andrea L. Cheek and Frederick L. Cottrell, III terminated. Signed by Judge Leonard P. Stark on 2/8/22. (ntl)
February 8, 2022 Filing 483 REDACTED VERSION of (223 in 1:19-cv-02053-LPS, 479 in 1:20-md-02930-LPS) Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
February 8, 2022 Opinion or Order SO ORDERED, re (377 in 1:19-cv-01979-LPS, 482 in 1:20-md-02930-LPS) STIPULATION TO EXTEND TIME the Deadline for Novartis's Opposition to Defendant Noratech's Motion for Fees Pursuant to 35 U.S.C. 285 to February 16, 2022 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/8/22. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
February 7, 2022 Filing 482 STIPULATION TO EXTEND TIME the Deadline for Novartis's Opposition to Defendant Noratech's Motion for Fees Pursuant to 35 U.S.C. 285 to February 16, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
February 7, 2022 Filing 481 [SEALED] STIPULATION of Dimissal Pursuant to Rules 41(a)(2) and 41(c) by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
February 3, 2022 Opinion or Order SO ORDERED, re #480 STIPULATION TO EXTEND TIME for responsive and reply expert reports and close of expert discovery to the deadlines set forth in the stipulation filed by Zydus Pharmaceuticals (USA) Inc. Signed by Judge Leonard P. Stark on 2/3/22. (ntl)
February 3, 2022 Opinion or Order SO ORDERED, re (223 in 1:19-cv-02053-LPS, 479 in 1:20-md-02930-LPS) [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against MSN and MSN's Counterclaims Against the '938 and '134 Patents. Signed by Judge Leonard P. Stark on 2/2/22. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
February 2, 2022 Filing 480 STIPULATION TO EXTEND TIME for responsive and reply expert reports and close of expert discovery to the deadlines set forth in the stipulation - filed by Zydus Pharmaceuticals (USA) Inc.. (Poff, Adam)
January 31, 2022 Filing 479 [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against MSN and MSN's Counterclaims Against the '938 and '134 Patents by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
January 31, 2022 Opinion or Order SO ORDERED, re (222 in 1:19-cv-02053-LPS, 477 in 1:20-md-02930-LPS) STIPULATION TO EXTEND TIME for certain case deadlines related to expert discovery to various dates filed by Dr. Reddys Laboratories, Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd. Signed by Judge Leonard P. Stark on 1/31/22. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
January 27, 2022 Filing 478 NOTICE requesting Clerk to remove Leora Ben-Ami as co-counsel.. (Hoeschen, Nathan)
January 26, 2022 Filing 477 STIPULATION TO EXTEND TIME for certain case deadlines related to expert discovery to various dates - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc.. (Stamoulis, Stamatios)
January 18, 2022 Filing 476 REDACTED VERSION of (474 in 1:20-md-02930-LPS) Declaration,, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit G-H, #8 Exhibit I, #9 Exhibit J, #10 Exhibit K, #11 Exhibit L, #12 Exhibit M, #13 Exhibit N, #14 Exhibit O, #15 Exhibit P, #16 Exhibit Q, #17 Exhibit R, #18 Exhibit S, #19 Exhibits T-W, #20 Exhibit X)(Phillips, John)
January 18, 2022 Filing 475 REDACTED VERSION of (473 in 1:20-md-02930-LPS) Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Phillips, John)
January 10, 2022 Filing 474 [SEALED] DECLARATION re (472 in 1:20-md-02930-LPS, 370 in 1:19-cv-01979-LPS) MOTION for Attorney Fees Pursuant to 35 U.S.C. 285 of Don J. Mizerk by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit G, #8 Exhibit H, #9 Exhibit I, #10 Exhibit J, #11 Exhibit K, #12 Exhibit L, #13 Exhibit M, #14 Exhibit N, #15 Exhibit O, #16 Exhibit P, #17 Exhibit Q, #18 Exhibit R, #19 Exhibit S, #20 Exhibit T, #21 Exhibit U, #22 Exhibit V, #23 Exhibit W, #24 Exhibit X)(Phillips, John)
January 10, 2022 Filing 473 [SEALED] OPENING BRIEF in Support re #472 MOTION for Attorney Fees Pursuant to 35 U.S.C. 285 filed by Nanjing Noratech Pharmaceutical Co., Limited.Answering Brief/Response due date per Local Rules is 1/24/2022. (Phillips, John)
January 10, 2022 Filing 472 MOTION for Attorney Fees Pursuant to 35 U.S.C. 285 - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: #1 Proposed Order)(Phillips, John)
January 7, 2022 Filing 471 NOTICE OF SERVICE of (1) Supplemental Opening Expert Report of Dr. Alexander M. Klibanov on Infringement by Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. and (2) Supplemental Opening Expert Report of Francis G. Spinale, MD, PHD, on Infringement by Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
January 6, 2022 Filing 470 NOTICE of Withdrawal of Appearance of Amit Singhai by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Ormerod, Eve)
January 4, 2022 Opinion or Order SO ORDERED, re (369 in 1:19-cv-01979-LPS, 469 in 1:20-md-02930-LPS) STIPULATION TO EXTEND TIME for Noratech to file any motion for attorneys fees and/or costs under Fed. R. Civ. P. 54(d) and/or Local Rules 54.l and/or 54.3, including any motion that this case is exceptional under 35 U.S.C. 285; and (2) Novartis' opposition to any such motion(s) to January 10, 2022 and February 9, 2022, respectively filed by Noratech Labs, Inc. Signed by Judge Leonard P. Stark on 1/3/22. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
December 22, 2021 Filing 469 STIPULATION TO EXTEND TIME for Noratech to file any motion for attorneys fees and/or costs under Fed. R. Civ. P. 54(d) and/or Local Rules 54.l and/or 54.3, including any motion that this case is exceptional under 35 U.S.C. 285; and (2) Novartiss opposition to any such motion(s). to January 10, 2022 and February 9, 2022, respectively. - filed by Noratech Labs, Inc.. (Haney, Megan)
December 21, 2021 Filing 468 REDACTED VERSION of #458 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Stipulation of Authenticity by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 21, 2021 Filing 467 REDACTED VERSION of (452 in 1:20-md-02930-LPS, 359 in 1:19-cv-01979-LPS) Stipulation, with Respect to Aurobindo Pharm USA, Inc. and Aurobindo Pharma Ltd. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 17, 2021 Filing 466 REDACTED VERSION of (361 in 1:19-cv-01979-LPS, 457 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
December 16, 2021 Filing 465 REDACTED VERSION of (214 in 1:19-cv-02053-LPS, 455 in 1:20-md-02930-LPS) Letter, by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd.. (Poff, Adam)
December 15, 2021 Filing 464 NOTICE OF SERVICE of Opening Expert Report of Laird Forrest Regarding Invalidity of U.S. Patent Nos. 8,101,659 and 8,796,331 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
December 15, 2021 Filing 463 NOTICE OF SERVICE of Opening Expert Reports filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
December 15, 2021 Filing 462 REDACTED VERSION of (213 in 1:19-cv-02053-LPS, 454 in 1:20-md-02930-LPS) Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 15, 2021 Filing 461 REDACTED VERSION of (360 in 1:19-cv-01979-LPS, 453 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 15, 2021 Filing 460 NOTICE OF SERVICE of Opening Expert Report of Dan Fintel, M.D., on the Invalidity of the '659 and '331 Patents filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc..(Ormerod, Eve)
December 14, 2021 Filing 459 NOTICE OF SERVICE of Expert Report of Dr. Jonathan W. Steed filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard)
December 13, 2021 Filing 458 [SEALED] Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Stipulation of Authenticity. (Attachments: #1 Certificate of Service)(Silver, Daniel)
December 10, 2021 Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 12/10/2021. (Court Reporter B. Gaffigan.) Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
December 10, 2021 Filing 457 [SEALED] STIPULATION with respect to Crystal Pharamceutical (Suzhou) Co. LTD. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 10, 2021 Opinion or Order SO ORDERED, re #453 STIPULATION and [Proposed] Order Dismissing Nanjing Noratech Pharmaceutical Co., Limited From The Above-Captioned Actions -- Party Nanjing Noratech Pharmaceutical Co., Limited terminated. Attorney John C. Phillips, Jr; Masha Femi and Megan C. Haney terminated. Signed by Judge Leonard P. Stark on 12/9/21. (ntl)
December 9, 2021 Filing 456 REDACTED VERSION of (140 in 1:19-cv-02021-LPS, 110 in 1:20-cv-00074-LPS, 447 in 1:20-md-02930-LPS) Stipulation, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 9, 2021 Filing 455 [SEALED] Letter to The Honorable Leonard P. Stark from Adam W. Poff regarding Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Responsive Discovery Dispute Letter - re (454 in 1:20-md-02930-LPS) Letter,. (Attachments: #1 Exhibit A & B)(Poff, Adam)
December 9, 2021 Pro Hac Vice Attorney Whitney M. Howard for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk)
December 8, 2021 Filing 454 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Dispute Opening - re (212 in 1:19-cv-02053-LPS, 449 in 1:20-md-02930-LPS) Order Setting Teleconference,,,,. (Attachments: #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3, #4 Certificate of Service)(Silver, Daniel)
December 8, 2021 Filing 453 [SEALED] STIPULATION and [Proposed] Order Dismissing Nanjing Noratech Pharmaceutical Co., Limited From The Above-Captioned Actions by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 8, 2021 Filing 452 [SEALED] STIPULATION with Respect to Aurobindo Pharma USA, Inc. and Aurobindo Pharma, Ltd. Regarding Rule 30(b)(6) Depositions, ANDA No. 213631 and U.S. Patent Nos. 8,101,659 and 8,796,331 by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 7, 2021 Opinion or Order SO ORDERED, re (435 in 1:20-md-02930-LPS, 349 in 1:19-cv-01979-LPS) STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Lupin and Lupin's Counterclaims Against the '938 and '134 Patents filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 12/6/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
December 7, 2021 Opinion or Order SO ORDERED, re (353 in 1:19-cv-01979-LPS, 442 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Alkem and Alkem's Counterclaims Against the '938 and '134 Patents filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 12/6/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
December 7, 2021 Opinion or Order SO ORDERED, re (434 in 1:20-md-02930-LPS, 348 in 1:19-cv-01979-LPS) STIPULATION of Novartis, Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Inc., and Lupin Pharmaceuticals, Inc. filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 12/6/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
December 7, 2021 Opinion or Order SO ORDERED, re (140 in 1:19-cv-02021-LPS, 110 in 1:20-cv-00074-LPS, 447 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Alembic and Alembic's Counterclaims Against the '938 and '134 Patents filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 12/6/21. Associated Cases: 1:19-cv-02021-LPS, 1:20-cv-00074-LPS, 1:20-md-02930-LPS (ntl)
December 6, 2021 Filing 451 REDACTED VERSION of (353 in 1:19-cv-01979-LPS, 442 in 1:20-md-02930-LPS) Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
December 6, 2021 Filing 450 REDACTED VERSION of (352 in 1:19-cv-01979-LPS, 441 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
December 6, 2021 Opinion or Order Filing 449 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for December 10, 2021 at 4:45 p.m. The parties and any interested members of the public can access the teleconference by dialing 877-336-1829 and using the access code 1408971. IT IS FURTHER ORDERED that not later than December 8, 2021 any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than December 9, 2021, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 12/6/2021. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
December 3, 2021 Opinion or Order SO ORDERED, re (437 in 1:20-md-02930-LPS, 350 in 1:19-cv-01979-LPS) STIPULATION TO EXTEND TIME expert report deadlines to Opening expert reports 12/14/2021; Rebuttal expert reports 2/3/2022; Reply expert reports 3/24/2022 filed by Teva Pharmaceuticals USA, Inc. Signed by Judge Leonard P. Stark on 12/2/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
December 2, 2021 Filing 448 REDACTED VERSION of (345 in 1:19-cv-01979-LPS, 426 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 2, 2021 Filing 447 [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Alembic and Alembic's Counterclaims Against the '938 and '134 Patents by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
December 1, 2021 Filing 446 REDACTED VERSION of (435 in 1:20-md-02930-LPS, 349 in 1:19-cv-01979-LPS) Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
December 1, 2021 Filing 445 REDACTED VERSION of (434 in 1:20-md-02930-LPS, 348 in 1:19-cv-01979-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 30, 2021 Filing 444 NOTICE of Appearance by Richard Charles Weinblatt on behalf of MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. (Weinblatt, Richard)
November 30, 2021 Filing 443 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling a Discovery Teleconference. (Silver, Daniel)
November 30, 2021 Opinion or Order SO ORDERED, re (424 in 1:20-md-02930-LPS, 37 in 1:21-cv-00229-LPS) MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Laura K. Fishwick, Gregory J. Manas, and Whitney Meier Howard filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/30/21. Associated Cases: 1:21-cv-00229-LPS, 1:20-md-02930-LPS (ntl)
November 29, 2021 Filing 442 [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Alkem and Alkem's Counterclaims Against the '938 and '134 Patents by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 29, 2021 Filing 441 [SEALED] STIPULATION with Respect to Alkem Laboratories Ltd. by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 29, 2021 Filing 440 REDACTED VERSION of (344 in 1:19-cv-01979-LPS, 425 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 29, 2021 Filing 439 REDACTED VERSION of (423 in 1:20-md-02930-LPS, 136 in 1:19-cv-02021-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 29, 2021 Filing 438 REDACTED VERSION of (420 in 1:20-md-02930-LPS, 135 in 1:19-cv-02021-LPS, 108 in 1:20-cv-00074-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 24, 2021 Filing 437 STIPULATION TO EXTEND TIME expert report deadlines to Opening expert reports 12/14/2021; Rebuttal expert reports 2/3/2022; Reply expert reports 3/24/2022 - filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan)
November 24, 2021 Filing 436 REDACTED VERSION of (412 in 1:20-md-02930-LPS, 158 in 1:20-cv-00445-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 24, 2021 Filing 435 [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Lupin and Lupin's Counterclaims Against the '938 and '134 Patents by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 24, 2021 Filing 434 [SEALED] STIPULATION of Novartis, Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Inc., and Lupin Pharmaceuticals, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 24, 2021 Filing 433 REDACTED VERSION of (342 in 1:19-cv-01979-LPS, 419 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 24, 2021 Filing 432 REDACTED VERSION of (340 in 1:19-cv-01979-LPS, 415 in 1:20-md-02930-LPS) Stipulation of Dismissal, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 24, 2021 Filing 431 REDACTED VERSION of (203 in 1:19-cv-02053-LPS, 417 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 24, 2021 Filing 430 REDACTED VERSION of (202 in 1:19-cv-02053-LPS, 416 in 1:20-md-02930-LPS) Stipulation of Dismissal by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 24, 2021 Filing 429 REDACTED VERSION of (414 in 1:20-md-02930-LPS, 201 in 1:19-cv-02053-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 24, 2021 Filing 428 REDACTED VERSION of (200 in 1:19-cv-02053-LPS, 413 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 24, 2021 Filing 427 REDACTED VERSION of (133 in 1:19-cv-02021-LPS, 411 in 1:20-md-02930-LPS) Stipulation of Dismissal by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 23, 2021 Filing 426 [SEALED] STIPULATION With Respect to Laurus Labs Limited and Laurus Generics Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 23, 2021 Opinion or Order SO ORDERED, re (344 in 1:19-cv-01979-LPS, 425 in 1:20-md-02930-LPS) STIPULATION of Novartis, Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc. filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/23/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
November 22, 2021 Filing 425 [SEALED] STIPULATION of Novartis, Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc. by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 22, 2021 Opinion or Order SO ORDERED, re (202 in 1:19-cv-02053-LPS, 416 in 1:20-md-02930-LPS) STIPULATION of Dismissal of Novartis's '938 and '134 Patent Claims Against Hetero and Hetero's Counterclaims Against the '938 and '134 Patents filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/22/21. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
November 22, 2021 Opinion or Order SO ORDERED, re (340 in 1:19-cv-01979-LPS, 415 in 1:20-md-02930-LPS) STIPULATION of Dismissal of Novartis's '938 and '134 Patent Claims Against Torrent and Torrent's Counterclaims Against the '938 and '134 Patents filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/22/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
November 22, 2021 Opinion or Order SO ORDERED, re (203 in 1:19-cv-02053-LPS, 417 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Staying Litigation with Respect to Novugen Pharma (Malaysia) SDN, BHD filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/22/21. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
November 19, 2021 Filing 424 MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Laura K. Fishwick, Gregory J. Manas, and Whitney Meier Howard - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Laura K. Fishwick, Gregory J. Manas, and Whitney Meier Howard)(Silver, Daniel)
November 19, 2021 Filing 423 [SEALED] STIPULATION With Respect to Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc. by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 19, 2021 Filing 422 NOTICE OF SERVICE of Crystal Pharmaceutical (Suzhou) Co., Ltd.'s production of documents labeled CRYSAVA217712-CRYSAVA217735 [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
November 19, 2021 CORRECTING ENTRY: D.I. 423 previously deleted per counsels request. (apk)
November 18, 2021 Filing 421 REDACTED VERSION of (199 in 1:19-cv-02053-LPS, 410 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 18, 2021 Filing 420 [SEALED] STIPULATION with Respect to Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 17, 2021 Filing 419 [SEALED] STIPULATION With Respect to Defendant Teva Pharmaceuticals USA, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 17, 2021 Opinion or Order SO ORDERED, re (133 in 1:19-cv-02021-LPS, 411 in 1:20-md-02930-LPS) STIPULATION of Dismissal of Novartis's '938 and '134 Patent Claims Against Macleods and Macleods's Conterclaims Against the '938 Patent. Signed by Judge Leonard P. Stark on 11/17/21. Associated Cases: 1:19-cv-02021-LPS, 1:20-md-02930-LPS (ntl)
November 16, 2021 Filing 418 REDACTED VERSION of (196 in 1:19-cv-02053-LPS, 114 in 1:20-cv-00415-LPS, 339 in 1:19-cv-01979-LPS, 132 in 1:19-cv-02021-LPS, 35 in 1:21-cv-00229-LPS, 106 in 1:20-cv-00074-LPS, 157 in 1:20-cv-00445-LPS, 407 in 1:20-md-02930-LPS) Status Report by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
November 16, 2021 Filing 417 [SEALED] STIPULATION and [Proposed] Order Staying Litigation with Respect to Novugen Pharma (Malaysia) SDN, BHD by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 16, 2021 Filing 416 [SEALED] STIPULATION of Dismissal of Novartis's '938 and '134 Patent Claims Against Hetero and Hetero's Counterclaims Against the '938 and '134 Patents by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 16, 2021 Filing 415 [SEALED] STIPULATION of Dismissal of Novartis's '938 and '134 Patent Claims Against Torrent and Torrent's Counterclaims Against the '938 and '134 Patents by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 15, 2021 Filing 414 [SEALED] STIPULATION With Respect to MSN Pharmaceutical Inc. MSN Laboratories Private Limited, and MSN Life Sciences Private Limited by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 15, 2021 Filing 413 [SEALED] STIPULATION With Respect to Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratoties, Ltd. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 15, 2021 Filing 412 [SEALED] STIPULATION with Respect to Mylan Pharmaceuticals, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 15, 2021 Filing 411 [SEALED] STIPULATION of Dismissal of Novartis's '938 and '134 Patent Claims Against Macleods and Macleods's Conterclaims Against the '938 Patent by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 12, 2021 Opinion or Order SO ORDERED, re (199 in 1:19-cv-02053-LPS, 410 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Novugen filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/12/21. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
November 10, 2021 Filing 410 [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Novugen by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 9, 2021 Filing 409 NOTICE of Withdrawal of Beth A. Swadley, Esquire by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc. (Poff, Adam)
November 9, 2021 Filing 408 NOTICE of Withdrawal of Beth A. Swadley by Novugen Pharma (Malaysia) Sdn. Bhd. (Poff, Adam)
November 9, 2021 Pro Hac Vice Attorney Whitney M. Howard for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-LPS et al.(srs)
November 8, 2021 Filing 407 [SEALED] Interim STATUS REPORT Joint by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
November 8, 2021 Filing 406 NOTICE of Withdrawal of Beth A. Swadley by Laurus Generics Inc., Laurus Labs Limited (Poff, Adam)
November 8, 2021 Opinion or Order SO ORDERED, re (156 in 1:20-cv-00445-LPS, 131 in 1:19-cv-02021-LPS, 105 in 1:20-cv-00074-LPS, 195 in 1:19-cv-02053-LPS, 337 in 1:19-cv-01979-LPS, 405 in 1:20-md-02930-LPS, 113 in 1:20-cv-00415-LPS) MOTION for Pro Hac Vice Appearance of Attorney Whitney Meier Howard filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/8/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl)
November 5, 2021 Filing 405 MOTION for Pro Hac Vice Appearance of Attorney Whitney Meier Howard - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certification for Whitney Meier Howard)(Silver, Daniel)
November 4, 2021 Opinion or Order SO ORDERED, re (336 in 1:19-cv-01979-LPS, 104 in 1:20-cv-00074-LPS, 404 in 1:20-md-02930-LPS, 194 in 1:19-cv-02053-LPS, 130 in 1:19-cv-02021-LPS, 155 in 1:20-cv-00445-LPS, 112 in 1:20-cv-00415-LPS, 34 in 1:21-cv-00229-LPS) STIPULATION TO EXTEND TIME the Deadline for the Submissionof the Joint Status Report to November 8, 2021 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/4/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl)
November 3, 2021 Filing 404 STIPULATION TO EXTEND TIME the Deadline for the Submissionof the Joint Status Report to November 8, 2021 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
October 25, 2021 Filing 403 NOTICE OF SERVICE of Hetero's Objections and Responses to Plaintiff's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Hetero USA Inc., Hetero Labs Limited and Hetero Labs Limited Unit III filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,.(Ormerod, Eve)
October 25, 2021 Filing 402 NOTICE OF SERVICE of Torrent's Objections and Responses to Plaintiff's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve)
October 25, 2021 Filing 401 NOTICE OF SERVICE of (1) Biocon's response to Plaintiff's First Set of Requests for Admission (Nos. 1-27); (2) Biocon's response to Plaintiff's Fourth Set of Requests for Production (No. 85); (3) Biocon's response to Plaintiff's Third Set of Interrogatories (No. 6); and (4) Biocon's objections to Plaintiff's 30(b)(6) Deposition Notice filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Dorsney, Kenneth)
October 21, 2021 Filing 400 NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Requests for Admission (Nos. 1-18); (2) Novartis's Objections and Responses to Defendant Teva's First Set of Requests for Admissions (Nos. 1-9); (3) Novartis's Objections and Responses to Defendant Teva's First Set of Individual Interrogatories (Nos. 1-9); and (4) Novartis's Objections and Responses to Defendant Zydus's First Set of Requests for Admissions (Nos. 1-8) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
October 21, 2021 Filing 399 NOTICE OF SERVICE of (1)Defendants Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Inc., and Lupin Pharmaceuticals, Inc.s Responses to Plaintiffs First Set of Common Requests for Admission (Nos. 1-27); (2) Objections and Responses to Plaintiffs Fourth Set of Requests for the Production of Documents and Things (No. 138); (3) Objections and Responses to Plaintiffs Third Set of Interrogatories to Lupin (No. 6) filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
October 21, 2021 Filing 398 NOTICE OF SERVICE of 1) Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Fourth Set of Requests for Production (No. 87); 2) Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Third Set of Interrogatories (No. 6); 3) Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss First Set of Requests for Admissions (Nos. 1-27); and 4) Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Response to Novartiss Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth)
October 21, 2021 Filing 397 NOTICE OF SERVICE of 1) Defendants Laurus Labs Limited and Laurus Generics Inc.'s First Supplemental Responses and Objections to Plaintiff's Second Set of Interrogatories (Nos. 3-5); 2) Defendants Laurus Labs Limited and Laurus Generics Inc.'s Responses and Objections to Plaintiff's Notice of Deposition; 3) Defendants Laurus Labs Limited and Laurus Generics Inc.'s Responses and Objections to Plaintiff's First Set of Requests for Admission (Nos. 1-27); 4) Defendants Laurus Labs Limited and Laurus Generics Inc.'s Responses and Objections to Plaintiff's Third Set of Interrogatories (Nos. 6); and 5) Defendants Laurus Labs Limited and Laurus Generics Inc.'s Responses and Objections to Plaintiff's Fourth Set of Requests for Production (Nos. 75) filed by Laurus Generics Inc., Laurus Labs Limited.(Swadley, Beth)
October 21, 2021 Filing 396 NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's Fourth Set Of Requests To Mylan Pharmaceuticals Inc. For The Production Of Documents And Things (Nos. 75-76) [Highly Confidential Attorneys' Eyes Only]; Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's Third Set Of Interrogatories (No. 6) To Mylan Pharmaceuticals Inc. [Highly Confidential Attorneys' Eyes Only]; Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's First Set Of Requests For Admission To Mylan Pharmaceuticals Inc. [Highly Confidential Attorneys' Eyes Only]; and Mylan Pharmaceuticals Inc.'s Second Supplemental Responses And Objections To Novartis's Second Set Of Interrogatories To Mylan Pharmaceuticals Inc. (Nos. 3-5) [Highly Confidential Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
October 20, 2021 Filing 395 NOTICE OF SERVICE of Defendants Objections and Responses to Novartiss Second Set of Common Interrogatories to Defendants (No. 2) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
October 20, 2021 Filing 394 NOTICE OF SERVICE of (1) Defendants Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd. Amended Initial Disclosures Pursuant to Fed. R. Civ. P. 16(a)(1), (2) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s Second Supplemental Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5), (3) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss Third Set of Interrogatories to DRL (No. 6), (4) Dr. Reddys Laboratories, Inc.s and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss Fourth Set of Requests to Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd. for the Production of Documents and Things (No. 75), and (5) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd. Objections and Responses to Novartiss First Set of Requests for Admission (Nos. 1-50) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
October 20, 2021 Filing 393 NOTICE OF SERVICE of (1) MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Objections and Responses to Novartiss Third Set of Interrogatories to DRL (No. 6), (2) MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Plaintiffs Fifth Set of Requests for the Production of Documents and Things, and (3) MSN Pharmaceuticals, Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Plaintiffs First Set of Requests for Admissions filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios)
October 20, 2021 Filing 392 NOTICE OF SERVICE of 1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Third Set of Interrogatories (No. 6); 2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Fourth Set of Requests for The Production of Documents and Things (Nos. 75-76); 3) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's First Set of Requests for Admission (Nos. 1-50); and 4) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Second Supplemental Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
October 20, 2021 Filing 391 NOTICE OF SERVICE of 1. Teva's Responses to Novartis's Third Set of Interrogatories (No. 6) 2. Teva's Responses and Objections to Novartis's Fourth Set of Requests for the Production of Documents and Things (Nos. 75-83) 3. Teva's Second Supplemental Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) 4. Teva's Objections and Responses to Novartis's First Set of Request for Admissions filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
October 20, 2021 Filing 390 NOTICE OF SERVICE of 1) Torrent's Objections and Responses to Plaintiff's Third Set of Interrogatories to Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. (No. 6), 2) Torrent's Objections and Responses to Novartis's Fourth Set of Requests to Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. for the Production of Documents and Things (No. 75), and 3) Torrent's Objections and Responses to Plaintiff's First Set of Requests for Admission to Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. (Nos. 1-27) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve)
October 20, 2021 Filing 389 NOTICE OF SERVICE of 1) Hetero's Objections and Responses to Plaintiff's Third Set of Interrogatories to Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III (No. 6), 2) Hetero's Objections and Responses to Novartis's Fourth Set of Requests to Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III for the Production of Documents and Things (No. 75), and 3) Hetero's Objections and Responses to Novartis's First Set of Requests for Admission to Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III (Nos. 1-27) filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,.(Ormerod, Eve)
October 20, 2021 Filing 388 NOTICE OF SERVICE of (1) Aurobindo's responses to Plaintiff's First Set of Requests for Admission (Nos. 1-27); (2) Aurobindo's response to Plaintiff's Third Set of Interrogatories (No. 6); and (3) Aurobindo's response to Plaintiff's Fourth Set of Requests for Production (No. 75) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Hitch, Cortlan)
October 20, 2021 Filing 387 NOTICE OF SERVICE of Crystal Pharmaceutical (Suzhou) Co., Ltd.'s documents bates labeled CRYSAVA216756 CRYSAVA216776 [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
October 20, 2021 Filing 386 NOTICE OF SERVICE of (i) Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Responses to Novartis's Fourth Set of Requests for the Production of Documents and Things (Nos. 75-83) [HIGHLY CONFIDENTIAL]; (ii) Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Responses to Novartis's First Set of Requests for Admissions (Nos. 1-50) [HIGHLY CONFIDENTIAL]; (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Objections and Responses to Plaintiff Novartis's Notice of Rule 30(b)(6) Deposition [HIGHLY CONFIDENTIAL]; (iv) Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Response to Novartis's Third Set of Interrogatories (No. 6) [HIGHLY CONFIDENTIAL]; and, (v) Crystal Pharmaceutical (Suzhou) Co., Ltd.'s First Supplemental Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) [CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
October 20, 2021 Filing 385 NOTICE OF SERVICE of (i) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's First Set of Requests for Admission (Nos. 1-27); (ii) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's Third Set of Interrogatories (No. 6); (iii) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's Fourth Set of Requests for the Production of Documents and Things (No. 75); and (iv) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Supplemental Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John)
October 20, 2021 Filing 384 NOTICE of Appearance by April M. Kirby on behalf of Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. (Kirby, April)
October 20, 2021 Filing 383 NOTICE to Take Deposition of Michael Motto on October 22, 2021 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
October 20, 2021 Filing 382 NOTICE OF SERVICE of (1) Alkem's Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-27); (2) Alkem's Responses to Plaintiffs' Third Set of Interrogatories (No. 6) and; (3) Alkem's Responses to Plaintiffs' Fourth Set of Requests for Production (No. 75) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth)
October 20, 2021 Filing 381 NOTICE OF SERVICE of 1) Alembic Defendants' Response to Plaintiff's First Set of Requests for Admissions (Nos. 1-50), 2) Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's Third Set of Interrogatories (No. 6), and 3) Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's Fourth Set of Requests for the Production of Documents and Things (No. 75) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Ormerod, Eve)
October 20, 2021 Filing 380 NOTICE OF SERVICE of Novartis's Second Supplemental Response to Defendants' Interrogatory No. 3 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
October 19, 2021 Filing 379 NOTICE OF SERVICE of Discovery Responses filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
October 18, 2021 Filing 378 NOTICE OF SERVICE of MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Plaintiffs Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios)
October 18, 2021 Filing 377 REDACTED VERSION of (311 in 1:19-cv-01979-LPS, 363 in 1:20-md-02930-LPS) Letter by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
October 18, 2021 Filing 376 REDACTED VERSION of (362 in 1:20-md-02930-LPS, 310 in 1:19-cv-01979-LPS) Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
October 18, 2021 Filing 375 REDACTED VERSION of (312 in 1:19-cv-01979-LPS, 364 in 1:20-md-02930-LPS) Letter, by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan)
October 18, 2021 Filing 374 REDACTED VERSION of (361 in 1:20-md-02930-LPS, 309 in 1:19-cv-01979-LPS) Letter, by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan)
October 18, 2021 Filing 373 NOTICE OF SERVICE of Alkem's Objections and Responses to Plaintiff's Notice of 30(b)(6) Deposition Notice to Alkem filed by Alkem Laboratories Ltd..(Hitch, Cortlan)
October 18, 2021 Filing 372 NOTICE OF SERVICE of Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Responses and Objections to Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Ormerod, Eve)
October 15, 2021 Filing 371 NOTICE OF SERVICE of DRLs Objections and Responses to Novartiss Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd. filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
October 15, 2021 Filing 370 NOTICE OF SERVICE of (1) Defendants Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Inc., and Lupin Pharmaceuticals, Inc.'s Second Supplemental Objections and Responses to Plaintiff's Second Set of Interrogatories to Lupin (Nos. 3-5) and (2) Defendants Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Inc., and Lupin Pharmaceuticals, Inc.'s Objections and Responses to Plaintiffs' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) (Topics 1-13) filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
October 15, 2021 Filing 369 NOTICE OF SERVICE of Novartis's Objections and Responses to Defendant Crystal's Second Set of Individual Interrogatories (No. 4) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
October 14, 2021 Filing 368 NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's Notice Of Deposition Under Fed. R. Civ. P. 30(b)(6) To Mylan Pharmaceuticals Inc. [Highly Confidential Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
October 14, 2021 Filing 367 NOTICE OF SERVICE of Teva's Objections and Responses to Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
October 14, 2021 Filing 366 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
October 13, 2021 Opinion or Order Filing 365 ORAL ORDER: Having reviewed the parties' letters regarding discovery disputes (20-md-2930-LPS D.I. 361-64), IT IS HEREBY ORDERED that: (1) Novartis' request to order Teva to supplement its non-infringement interrogatory responses prior to the October 20 close of fact discovery is DENIED AS MOOT, in light of Teva's representation that it will do so (D.I. 364 at 1); and (2) Teva's request to order Novartis to produce documents relied upon in its infringement contentions and supplement its infringement contentions is DENIED WITHOUT PREJUDICE to renew during expert discovery. Novartis' refusal to produce evidence relating to testing of Teva's product Novartis has undertaken - for example, lab notebooks reflecting such testing, instrument scans and outputs, memos or reports describing or relating to the design of the tests, testing, analysis, results, and any testing and analysis of the reference standards relating to Teva's ANDA product - undermines Teva's ability to formulate and disclose its non-infringement position (meaning, among other things, Novartis may well be disappointed with the level of substance it will receive in Teva's soon-to-be-supplemented interrogatory responses) and raises concern that Novartis may not, in fact, have a good faith belief it can prove infringement of the asserted claims of the patents at issue. Nevertheless, the scheduling order is silent as to whether Novartis is required to produce evidence of its purportedly incomplete testing prior to the start of expert discovery and the Court is not persuaded, at present, that Teva is unduly prejudiced by the Court holding Novartis only to its obligations under the scheduling order. Should Teva believe, after receiving Novartis' expert report on infringement, that it is entitled to more discovery, and should Novartis refuse, Teva may renew its request to the Court. IT IS FURTHER ORDERED that the teleconference scheduled for later today is CANCELLED. ORDERED by Judge Leonard P. Stark on 10/13/21. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS (ntl)
October 12, 2021 Filing 364 [SEALED] Letter to The Honorable Leonard P. Stark from Nathan R. Hoeschen regarding response to Plaintiff's October 11, 2021 Discovery Dispute Letter - re (362 in 1:20-md-02930-LPS, 310 in 1:19-cv-01979-LPS) Letter,. (Attachments: #1 Exhibit 3)(Hoeschen, Nathan)
October 12, 2021 Filing 363 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Responsive Discovery Dispute. (Attachments: #1 Exhibit A, #2 Certificate of Service)(Silver, Daniel)
October 11, 2021 Filing 362 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Teva's Non-Infringement Contentions - re (358 in 1:20-md-02930-LPS, 307 in 1:19-cv-01979-LPS) Order Setting Teleconference,,,,. (Attachments: #1 Certificate of Service)(Silver, Daniel)
October 11, 2021 Filing 361 [SEALED] Letter to The Honorable Leonard P. Stark from Nathan R. Hoeschen regarding Discovery Dispute - re (358 in 1:20-md-02930-LPS, 307 in 1:19-cv-01979-LPS) Order Setting Teleconference,,,,. (Attachments: #1 Exhibit 1, #2 Exhibit 2)(Hoeschen, Nathan)
October 11, 2021 Filing 360 NOTICE OF SERVICE of Crystal Pharmaceutical (Suzhou) Co., Ltd.'s First Supplemental Responses to Novartis's First Set of Interrogatories (Nos. 1-2) [CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
October 8, 2021 Filing 359 NOTICE OF SERVICE of MSN Pharmaceuticals Inc.s, MSN Laboratories Private Limiteds and MSN Life Sciences Private Limiteds Supplemental Response to Plaintiffs Second Set of Interrogatories (Nos. 3-5) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios)
October 8, 2021 Opinion or Order Filing 358 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for October 13, 2021 at 4:45 p.m. The parties and any interested members of the public can access the teleconference by dialing 877-336-1829 and using the access code 1408971. IT IS FURTHER ORDERED that not later than October 11, 2021, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than October 12, 2021, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 10/8/2021. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS (ntl)
October 5, 2021 Filing 357 Letter to The Honorable Leonard P. Stark from Nathan R. Hoeschen regarding request for a Discovery Dispute Teleconference. (Hoeschen, Nathan)
October 1, 2021 Filing 356 NOTICE to Take Deposition of Michael Exton on October 5, 2021 filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios)
September 23, 2021 Pro Hac Vice Attorney Alina Afinogenova for Teva Pharmaceuticals USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk)
September 23, 2021 Opinion or Order SO ORDERED, re (304 in 1:19-cv-01979-LPS, 355 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Alina Afinogenova filed by Teva Pharmaceuticals USA, Inc. Signed by Judge Leonard P. Stark on 9/23/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
September 22, 2021 Filing 355 MOTION for Pro Hac Vice Appearance of Attorney Alina Afinogenova - filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan)
September 21, 2021 Filing 354 NOTICE OF SERVICE of Zydus's First Set of Individual Requests for Admission (Nos. 1-10) to Plaintiff Novartis Pharmaceuticals Corporation filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
September 21, 2021 Filing 353 NOTICE OF SERVICE of (1) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Defendants, (2) Novartis's Third Set Of Interrogatories To Defendants, (3) Novartis's Fourth Set of Requests to Defendants for the Production of Documents and Things, (4) Novartis's First Set Of Requests For Admissions To Defendants, and (5) Novartis's Second Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
September 20, 2021 Filing 352 NOTICE OF SERVICE of Defendants' First Set of Requests for Admissions (Nos. 1-18) to Plaintiff Novartis Pharmaceuticals Corporation filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
September 20, 2021 Filing 351 NOTICE OF SERVICE of (1) Teva's First Set of Interrogatories (Nos. 1-9) to Plaintiff Novartis Pharmaceuticals Corporation (2) Teva's First Set of Requests for Admissions (Nos. 1-10) to Plaintiff Novartis Pharmaceuticals Corporation filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
September 20, 2021 Filing 350 NOTICE OF SERVICE of 1) Zydus's First Set of Individual Requests for the Production of Documents and Things (Nos. 1-2) to Plaintiff Novartis Pharmaceuticals Corporation; and 2) Zydus's First Set of Individual Interrogatories (Nos. 1-4) to Plaintiff Novartis Pharmaceuticals Corporation filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
September 20, 2021 Filing 349 NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' Notice of Deposition to Plaintiff Pursuant to Fed. R. Civ. P. 30(b)(6) and (2) Plaintiff's Second Supplemental Infringement Contentions Against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
September 17, 2021 Filing 348 NOTICE OF SERVICE of Defendants Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Inc., and Lupin Pharmaceuticals, Inc.'s First Set of Interrogatories (Nos. 1-3) filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
September 17, 2021 Filing 347 NOTICE OF SERVICE of Defendants' Supplemental Joint Invalidity Contentions filed by Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Dorsney, Kenneth)
September 16, 2021 Filing 346 NOTICE OF SERVICE of Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s Second Supplemental Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
September 16, 2021 Filing 345 NOTICE OF SERVICE of Defendants' Second Set of Interrogatories (Nos. 8-11) to Plaintiff Novartis and Defendants' Second Set of Joint Requests for the Production of Documents and Things (No. 109) to Plaintiff Novartis filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 15, 2021 Filing 344 NOTICE to Take Deposition of Thomas J. Blacklock on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 15, 2021 Filing 343 NOTICE to Take Deposition of Piotr Karpinski on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 15, 2021 Filing 342 NOTICE to Take Deposition of Michael J. Girgis on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 15, 2021 Filing 341 NOTICE to Take Deposition of Mahavir Prashad on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 15, 2021 Filing 340 NOTICE to Take Deposition of Lili Feng on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 15, 2021 Filing 339 NOTICE to Take Deposition of Bin Hu on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 15, 2021 Filing 338 NOTICE to Take Deposition of Paul Sutton on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 15, 2021 Filing 337 NOTICE to Take Deposition of Sven Erik Godtfredsen on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 15, 2021 Filing 336 NOTICE to Take Deposition of Yugang Liu on on a mutually agreed-upon date filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 14, 2021 Filing 335 NOTICE OF SERVICE of Defendant Crystal Pharma's Second Set of Individual Interrogatories (No. 4) to Plaintiff Novartis Pharmaceuticals Corporation filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 13, 2021 Filing 334 NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s First Set of Individual Interrogatories (Nos. 1-4); and (2) Novartis's Objections and Responses to Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s First Set of Individual Requests for the Production of Documents and Things (Nos. 1-6) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
September 9, 2021 Filing 333 NOTICE of Joinder by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Ormerod, Eve)
September 8, 2021 Filing 332 NOTICE to Take Deposition of Randy Lee Webb on September 24, 2021 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 8, 2021 Filing 331 NOTICE to Take Deposition of NOVARTIS PHARMACEUTICALS CORPORATION on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 8, 2021 Opinion or Order Filing 330 ORAL ORDER: Having reviewed the parties' letters and related materials (see, e.g., D.I. 274, 276), IT IS HEREBY ORDERED that Defendant's request to compel Novartis "to immediately supplement its Infringement Contentions with... specificity" is DENIED. The Court has considered Defendant's letter (D.I. 282) suggesting that the parties' discovery dispute may soon be moot; however, absent further update from the parties, the Court understands that the dispute remains live. The Court need not make a determination as to whether Novartis' initial infringement contentions are sufficient because Defendant inexplicably waited more than eight months to dispute their sufficiency and, crucially, the agreed-upon scheduling order already requires Novartis to supplement its contentions by September 17, less than two weeks from now. Defendant has identified no meritorious basis at this point to require Novartis to supplement any sooner. ORDERED by Judge Leonard P. Stark on 9/8/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
September 7, 2021 Filing 329 NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd. produced documents labeled CRYSAVA216003 CRYSAVA216174 [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
August 31, 2021 Filing 328 NOTICE OF SERVICE of (1) Plaintiff's First Supplemental Infringement Contentions Against Defendants, and (2) Novartis's First Supplemental Objections and Responses to Defendant's First Set of Individual Interrogatories (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
August 30, 2021 Opinion or Order Filing 327 ORAL ORDER: For the reasons stated at the conclusion of the 2/25/21 hearing, IT IS HEREBY ORDERED that Defendants' motion for judgment on the pleadings (D.I. 20) is DENIED (See also D.I. 203 in related case 19-1979-LPS). ORDERED by Judge Leonard P. Stark on 8/30/21. (ntl)
August 27, 2021 Filing 326 REDACTED VERSION of (322 in 1:20-md-02930-LPS) Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
August 27, 2021 Filing 325 NOTICE OF SERVICE of Novartis's Second Supplemental Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-7) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
August 25, 2021 Filing 324 REDACTED VERSION of (320 in 1:20-md-02930-LPS) Letter by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: #1 Exhibit A)(Phillips, John)
August 22, 2021 Filing 323 NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Noratech's First Set of Interrogatories (Nos. 1-2) and (2) Novartis's Objections and Responses to Noratech's First Set of Requests for Admissions (Nos. 1-5) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
August 20, 2021 Filing 322 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Opposition to Defendant Noratech's August 18, 2021 - re (274 in 1:19-cv-01979-LPS, 320 in 1:20-md-02930-LPS) Letter. (Attachments: #1 Certificate of Service)(Silver, Daniel)
August 20, 2021 Filing 321 NOTICE OF SERVICE of Biocon's First Supplemental Responses and Objections to Novartis' Second Set of Interrogatories (Nos. 3-5) filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Hitch, Cortlan)
August 18, 2021 Filing 320 [SEALED] Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Discovery Dispute. (Attachments: #1 Exhibit A)(Phillips, John)
August 16, 2021 Opinion or Order Filing 319 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter (D.I. 270 in 19-1979), IT IS HEREBY ORDERED that not later than August 18, 2021, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than August 20, 2021, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. After reviewing the letter submissions, the Court may schedule a teleconference. ORDERED by Judge Leonard P. Stark on 8/16/21. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS (ntl)
August 12, 2021 Filing 318 NOTICE OF SERVICE of (1) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s First Set of Individual Requests for the Production of Documents and Things (Nos. 1-6) and (2) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s First Set of Individual Interrogatories (Nos. 1-4) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
August 4, 2021 Filing 317 REDACTED VERSION of #314 Statement Plaintiff's Answer to Lupin's Counterclaims by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
August 4, 2021 Filing 316 REDACTED VERSION of #313 Statement Plaintiffs' Answer to Lupin's Counterclaims by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
August 4, 2021 Filing 315 REDACTED VERSION of #312 Answer to Counterclaim by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
July 28, 2021 Filing 314 [SEALED] STATEMENT Plaintiff's Answer to Lupin's Counterclaims by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel)
July 28, 2021 Filing 313 [SEALED] STATEMENT Plaintiffs' Answer to Lupin's Counterclaims by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel)
July 28, 2021 Filing 312 [SEALED] ANSWER to #293 Answer to Amended Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel)
July 26, 2021 Filing 311 Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding requesting a Discovery Dispute Conference. (Phillips, John)
July 21, 2021 Filing 310 NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories to Plaintiff and Nanjing Noratech Pharmaceutical Co., Limited's First Set of Requests for Admission to Plaintiff filed by Nanjing Noratech Pharmaceutical Co., Limited.(Haney, Megan)
July 14, 2021 Filing 309 ANSWER to #282 Answer to Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 14, 2021 Filing 308 ANSWER to #289 Answer to Amended Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 14, 2021 Filing 307 ANSWER to #286 Answer to Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 14, 2021 Filing 306 ANSWER to #281 Answer to Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 14, 2021 Filing 305 ANSWER to #292 Answer to Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 14, 2021 Filing 304 ANSWER to #288 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 14, 2021 Filing 303 ANSWER to #280 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 14, 2021 Filing 302 ANSWER to #285 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 14, 2021 Filing 301 ANSWER to #284 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 14, 2021 Filing 300 REDACTED VERSION of #293 Answer to Amended Complaint,, Counterclaim, by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc.. (Ewing, Alexandra)
July 13, 2021 Filing 299 ANSWER to #277 Answer to Amended Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 13, 2021 Filing 298 ANSWER to #278 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 8, 2021 Filing 297 ANSWER to #274 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 8, 2021 Filing 296 ANSWER to #273 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 8, 2021 Opinion or Order Filing 295 ORDER re #294 MEMORANDUM OPINION re claim construction. Signed by Judge Leonard P. Stark on 7/8/2021. (etg)
July 8, 2021 Filing 294 MEMORANDUM OPINION re claim construction. Signed by Judge Leonard P. Stark on 7/8/2021. (etg)
July 8, 2021 Pro Hac Vice Attorney James E. Nealon for Aurobindo Pharma USA Inc., and for Aurobindo Pharma USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk)
July 7, 2021 Filing 293 [SEALED] ANSWER to Amended Complaint, re: #267 Amended Complaint and Lupin Atlantis Holdings, S.A.'s, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Pharmaceuticals, Inc., Lupin Limited.(Cottrell, Frederick)
June 29, 2021 Filing 292 ANSWER to Complaint , COUNTERCLAIM Answer, Separate Defenses, and Counterclaims to Plaintiff's Amended Complaint for Patent Infringement (Dkt. 145) against Novartis Pharmaceuticals Corporation by Dr. Reddys Laboratories, Ltd., Dr. Reddy's Laboratories, Inc..(Stamoulis, Stamatios)
June 29, 2021 Opinion or Order SO ORDERED, re (253 in 1:19-cv-01979-LPS, 25 in 1:21-cv-00229-LPS, 81 in 1:20-cv-00415-LPS, 279 in 1:20-md-02930-LPS) STIPULATION TO EXTEND TIME to answer the Amended Complaint to July 7, 2021 filed by Lupin Inc., Lupin Limited, Lupin Atlantis Holdings, S.A., Lupin Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 6/29/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-cv-00415-LPS, 1:20-md-02930-LPS, 1:21-cv-00229-LPS (ntl)
June 24, 2021 Filing 291 REDACTED VERSION of (24 in 1:21-cv-00229-LPS, 276 in 1:20-md-02930-LPS, 80 in 1:20-cv-00415-LPS, 250 in 1:19-cv-01979-LPS) Stipulation of Dismissal by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
June 23, 2021 Filing 290 ANSWER to Complaint Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Answer and Affirmative Defenses to Plaintiff's Amended Complaint by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Poff, Adam)
June 23, 2021 Filing 289 ANSWER to Amended Complaint, re: #269 Amended Complaint , Affirmative Defenses, and, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Mylan Pharmaceuticals Inc..(Moore, David)
June 23, 2021 Filing 288 ANSWER to Complaint , COUNTERCLAIM Biocon's Answer, Defenses and Counterclaims to the Amended Complaint (D.I. 265) against Novartis Pharmaceuticals Corporation by Biocon Pharma Limited, Biocon Limited.(Dorsney, Kenneth)
June 23, 2021 Filing 287 NOTICE of of Adoption by Nanjing Noratech Pharmaceutical Co., Limited (Phillips, John)
June 23, 2021 Filing 286 ANSWER to Complaint Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Answer to Amended Complaint and Counterclaims, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John)
June 23, 2021 Filing 285 ANSWER to Complaint (Amended), COUNTERCLAIM and Additional Defenses against Novartis Pharmaceuticals Corporation by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Ormerod, Eve)
June 23, 2021 Filing 284 ANSWER to Complaint (Amended), COUNTERCLAIM and Additional Defenses against Novartis Pharmaceuticals Corporation by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Ormerod, Eve)
June 23, 2021 Filing 283 ANSWER to Complaint , #270 Amended Complaint with Affirmative Defenses by Novugen Pharma (Malaysia) Sdn. Bhd..(Poff, Adam)
June 23, 2021 Filing 282 ANSWER to Complaint , COUNTERCLAIM - Teva Pharmaceuticals USA, Inc.'s Answer, Defenses and Counterclaims to the Amended Complaint (D.I. 265) against Novartis Pharmaceuticals Corporation by Teva Pharmaceuticals USA, Inc..(Keller, Karen)
June 23, 2021 Filing 281 ANSWER to Complaint [DEFENDANTS LAURUS LABS LTD. AND LAURUS GENERICS INC.'S ANSWER, DEFENSES, AND COUNTERCLAIMS TO PLAINTIFF'S AMENDED COMPLAINT], COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Laurus Generics Inc., Laurus Labs Limited.(Poff, Adam)
June 23, 2021 Filing 280 ANSWER to Complaint , COUNTERCLAIM -- Aurobindo's Answer, Defenses and Counterclaims to the Amended Complaint (D.I. 265) -- against Novartis Pharmaceuticals Corporation by Aurobindo Pharma USA Inc..(Dorsney, Kenneth)
June 22, 2021 Filing 279 STIPULATION TO EXTEND TIME to answer the Amended Complaint to July 7, 2021 - filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc.. (Ewing, Alexandra)
June 22, 2021 Filing 278 ANSWER to Complaint , COUNTERCLAIM -- Alkem's Answer, Defenses and Counterclaims to the Amended Complaint (D.I. 265) -- against Novartis Pharmaceuticals Corporation by Alkem Laboratories Ltd..(Dorsney, Kenneth)
June 22, 2021 Filing 277 ANSWER to Amended Complaint, re: #267 Amended Complaint Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Amended Answer to Plaintiff Novartis's Amended Complaint, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
June 21, 2021 Opinion or Order SO ORDERED, re (24 in 1:21-cv-00229-LPS, 276 in 1:20-md-02930-LPS, 80 in 1:20-cv-00415-LPS, 250 in 1:19-cv-01979-LPS) Stipulation and Order Dismissing Certain Claims filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 6/21/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-cv-00415-LPS, 1:20-md-02930-LPS, 1:21-cv-00229-LPS (ntl)
June 18, 2021 Filing 276 [SEALED] STIPULATION of Dismissal between Novartis and Lupin Dismissing Certain Claims by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
June 18, 2021 Filing 275 Official Transcript of Claim Construction Hearing held on June 8, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 7/9/2021. Redacted Transcript Deadline set for 7/19/2021. Release of Transcript Restriction set for 9/16/2021. (bpg)
June 17, 2021 Filing 274 ANSWER to Complaint Amended Complaint, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by MSN Pharmaceuticals Inc., MSN Life Sciences Private Limited, MSN Laboratories Private Limited.(Stamoulis, Stamatios)
June 17, 2021 Filing 273 ANSWER to Complaint Amended Complaint re D.I. 270, and Hetero USA, Inc.'s, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Hetero Labs Limited Unit III, Hetero Labs Limited, Hetero USA Inc.,.(Ormerod, Eve)
June 14, 2021 Pro Hac Vice Attorney Ronald M. Daignault, Richard Juang for MSN Laboratories Private Limited, for MSN Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (Associated Cases: 1:20-md-02930-LPS, 1:19-cv-02053-LPS) (myr)
June 11, 2021 Filing 272 Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding resolution of discovery dispute. (Cottrell, Frederick)
June 11, 2021 Opinion or Order SO ORDERED, re (146 in 1:19-cv-02053-LPS, 271 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Ronald M. Daignault and Richard Juang filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 6/11/21. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-02053-LPS (ntl)
June 10, 2021 Filing 271 MOTION for Pro Hac Vice Appearance of Attorney Ronald M. Daignault and Richard Juang - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Stamoulis, Stamatios)
June 9, 2021 Filing 270 AMENDED COMPLAINT against Cadila Healthcare Ltd., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Novugen Pharma (Malaysia) Sdn. Bhd., Zydus Pharmaceuticals (USA) Inc.- filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-D)(Silver, Daniel)
June 9, 2021 Filing 269 AMENDED COMPLAINT against Mylan Pharmaceuticals Inc.- filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-D)(Silver, Daniel)
June 9, 2021 Filing 268 AMENDED COMPLAINT against Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.- filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-D)(Silver, Daniel)
June 9, 2021 Filing 267 AMENDED COMPLAINT against Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc.- filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-D)(Silver, Daniel)
June 9, 2021 Filing 266 AMENDED COMPLAINT against Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc.- filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-D)(Silver, Daniel)
June 9, 2021 Filing 265 AMENDED COMPLAINT against Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc., Crystal Pharmaceutical (Suzhou) Co., Ltd., Laurus Generics Inc., Laurus Labs Limited, Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanjing Noratech Pharmaceutical Co., Limited, Teva Pharmaceuticals USA, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.- filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-D)(Silver, Daniel)
June 9, 2021 Filing 264 AMENDED COMPLAINT against Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.- filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-D)(Silver, Daniel)
June 9, 2021 Opinion or Order SO ORDERED, re (250 in 1:20-md-02930-LPS, 85 in 1:19-cv-02021-LPS, 66 in 1:20-cv-00415-LPS, 236 in 1:19-cv-01979-LPS, 13 in 1:21-cv-00229-LPS, 115 in 1:20-cv-00445-LPS, 63 in 1:20-cv-00074-LPS, 133 in 1:19-cv-02053-LPS) STIPULATION and [Proposed] Order Regarding Plaintiff Novartis Pharmaceuticals Corporation's Amended Complaints. Signed by Judge Leonard P. Stark on 6/9/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl)
June 8, 2021 Minute Entry for proceedings held before Judge Leonard P. Stark - Markman Hearing (by remote video) held on 6/8/2021. (Court Reporter B. Gaffigan.) Associated Cases: 1:20-md-02930-LPS et al. (ntl)
June 7, 2021 Filing 263 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Samples - re 261 Order,,. (Attachments: #1 Exhibit 1)(Gattuso, Dominick)
June 7, 2021 Filing 262 Letter to Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Dispute Letter - re (261 in 1:20-md-02930-LPS) Order,,. (Attachments: #1 Exhibit A)(Silver, Daniel)
June 4, 2021 Opinion or Order Filing 261 ORAL ORDER: Having reviewed the parties' letter regarding an inability to resolve a discovery dispute (D.I. 260), IT IS HEREBY ORDERED that the parties shall be prepared to discuss the matter at the presently scheduled Markman hearing on Tuesday, June 8, 2021. IT IS FURTHER ORDERED that not later than Monday, June 7, 2021, at 2:30 p.m., each party shall file a letter, not to exceed three (3) pages, outlining the issue in dispute and the party's position on that issue. ORDERED by Judge Leonard P. Stark on 6/4/21. (ntl)
June 4, 2021 Filing 260 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Request for Discovery Hearing. (Gattuso, Dominick)
June 3, 2021 Opinion or Order Filing 259 ORAL ORDER: IT IS HEREBY ORDERED that the Markman hearing on June 8, 2021 at 10:00 a.m. is available to the public using the following dial-in for audio access: +1 646 828 7666 US -- Meeting ID: 161 238 3790 -- Passcode: 824345 -- One Tap Mobile Public Dial-In Number: +16468287666,,1612383790#,,,,*824345# US. Audio reproduction of the proceeding is strictly prohibited. ORDERED by Judge Leonard P. Stark on 6/3/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl)
May 25, 2021 Filing 258 Letter to Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Claim Construction Hearing. (Attachments: #1 Exhibit 58)(Silver, Daniel)
May 24, 2021 Opinion or Order Filing 257 ORAL ORDER: Having reviewed the parties' letter concerning the claim construction hearing scheduled for June 8 at 10:00 a.m. (C.A. No. 20-md-2930 D.I. 256), IT IS HEREBY ORDERED that each side will be allocated 75 minutes for its presentation. The hearing will be conducted by videoconference technology. Defendants shall submit access information for the Court, including access information for any interested member of the public, in advance of the hearing. The parties may present argument in the order they propose in the letter. IT IS FURTHER ORDERED that each party shall submit any slides or other materials to be referenced at the hearing by no later than June 7 at 4:00 p.m. ORDERED by Judge Leonard P. Stark on 5/24/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl)
May 21, 2021 Filing 256 Letter to The Honorable Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Claim Construction Hearing. (Silver, Daniel)
May 21, 2021 Filing 255 APPENDIX re (14 in 1:21-cv-00229-LPS) Joint Claim Construction Brief, (88 in 1:19-cv-02021-LPS) Joint Claim Construction Brief, (69 in 1:20-cv-00415-LPS) Joint Claim Construction Brief, (118 in 1:20-cv-00445-LPS) Joint Claim Construction Brief, (136 in 1:19-cv-02053-LPS) Joint Claim Construction Brief, (253 in 1:20-md-02930-LPS) Joint Claim Construction Brief, (239 in 1:19-cv-01979-LPS) Joint Claim Construction Brief, (66 in 1:20-cv-00074-LPS) Joint Claim Construction Brief (Volume 2 -- Exhibits 1-57) by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-29, #2 Exhibit 35-43, #3 Exhibit 44, #4 Exhibit 45-57)(Silver, Daniel)
May 21, 2021 Filing 254 APPENDIX re (14 in 1:21-cv-00229-LPS) Joint Claim Construction Brief, (88 in 1:19-cv-02021-LPS) Joint Claim Construction Brief, (69 in 1:20-cv-00415-LPS) Joint Claim Construction Brief, (118 in 1:20-cv-00445-LPS) Joint Claim Construction Brief, (136 in 1:19-cv-02053-LPS) Joint Claim Construction Brief, (253 in 1:20-md-02930-LPS) Joint Claim Construction Brief, (239 in 1:19-cv-01979-LPS) Joint Claim Construction Brief, (66 in 1:20-cv-00074-LPS) Joint Claim Construction Brief (Volume 1 -- Exhibits A-D) by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-D)(Silver, Daniel)
May 21, 2021 Filing 253 JOINT CLAIM CONSTRUCTION BRIEF filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
May 20, 2021 Filing 252 NOTICE OF SERVICE of Defendants Objection to Plaintiffs Notice of Deposition of Raymond Butcher, Ph.D., Pursuant to Fed. R. Civ. P. 30(b)(1) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
May 19, 2021 Filing 251 STATEMENT re (241 in 1:20-md-02930-LPS, 228 in 1:19-cv-01979-LPS) Letter Novartis's Comments on Defendants' Technology Tutorial by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
May 18, 2021 Filing 250 STIPULATION and [Proposed] Order Regarding Plaintiff Novartis Pharmaceuticals Corporation's Amended Complaints by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-N)(Silver, Daniel)
May 17, 2021 Filing 249 NOTICE OF SERVICE of Defendants' Joint Sur-Reply Claim Construction Brief [with Exhibit 57]; and, (ii) the Declaration of Raymond Butcher, Ph.D. filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
May 17, 2021 Opinion or Order Filing 248 ORAL ORDER: IT IS HEREBY ORDERED that: (1) the claim construction hearing will be held remotely; (2) the claim construction hearing is RESCHEDULED to June 8, 2021 at 10:00 a.m.; and (3) the parties shall advise the Court, simultaneously with filing their joint claim construction brief, of the number of hours they request for the hearing and whether they prefer to proceed by video or telephone conference. ORDERED by Judge Leonard P. Stark on 5/17/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl)
May 17, 2021 Opinion or Order SO ORDERED, re (82 in 1:19-cv-02021-LPS, 60 in 1:20-cv-00074-LPS, 112 in 1:20-cv-00445-LPS, 247 in 1:20-md-02930-LPS, 233 in 1:19-cv-01979-LPS, 63 in 1:20-cv-00415-LPS, 12 in 1:21-cv-00229-LPS, 130 in 1:19-cv-02053-LPS) STIPULATION TO EXTEND TIME for Paintiff to Amend or Supplement Pleadings to May 18, 2021 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 5/17/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl)
May 14, 2021 Filing 247 STIPULATION TO EXTEND TIME Deadline for Paintiff to Amend or Supplement Pleadings to May 18, 2021 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
May 13, 2021 Filing 246 NOTICE OF SERVICE of Amended Rule 26(a) Initial Disclosures and Paragraph 3 Disclosures filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd..(Ormerod, Eve)
May 11, 2021 Filing 245 NOTICE of Deposition of Raymond Butcher, Ph.D., Pursuant to Fed. R. Civ. P. 30(b)(1) by Novartis Pharmaceuticals Corporation (Silver, Daniel)
May 10, 2021 Pro Hac Vice Attorney Mark C. McLennan for Teva Pharmaceuticals USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (amf)
May 7, 2021 Opinion or Order Filing 244 ORAL ORDER: Having reviewed the parties' letters relating to a claim construction deposition (D.I. 238, 242), IT IS HEREBY ORDERED that Defendants' request for an order compelling Plaintiff to produce Dr. Klibanov for a deposition by May 13, 2021 is GRANTED. Expert opinions and declarations constitute extrinsic evidence in the claim construction process and are at times unhelpful, particularly when that evidence is not subjected to the adversary process through cross-examination. While depositions need not occur in every claim construction proceeding, a party asking the Court to rely on such extrinsic evidence should expect to make its expert(s) available for deposition prior to a claim construction hearing, should the opposing party seek such a deposition within a reasonable timeframe. Defendants here timely noticed the deposition of Dr. Klibanov for May 5, 2021. Nothing in the operative scheduling order or this Court's general procedures precludes the deposition. Any prejudice accruing to Plaintiff can be cured by Plaintiff's presentation at the Markman hearing and through any appropriate post-hearing relief. Therefore, Plaintiff shall make Dr. Klibanov available for a deposition (not to exceed four hours in length) no later than May 13, 2021, on the topics identified by Defendants. IT IS FURTHER ORDERED that the teleconference scheduled for Monday, May 10, 2021 is CANCELLED. ORDERED by Judge Leonard P. Stark on 5/7/21. (ntl)
May 7, 2021 Pro Hac Vice Attorney Corey Weinstein for Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases 1:20-md-02930-LPS, 1:19-cv-02021-LPS. (apk)
May 6, 2021 Filing 243 APPENDIX re (242 in 1:20-md-02930-LPS) Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
May 6, 2021 Filing 242 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiff Novartis Pharmaceuticals Corporation's Responsive Discovery Letter Concerning Deposition of Dr. Klibanov - re (238 in 1:20-md-02930-LPS) Letter. (Silver, Daniel)
May 6, 2021 Opinion or Order SO ORDERED, re #239 MOTION for Pro Hac Vice Appearance of Attorney Mark C. McLennan filed by Teva Pharmaceuticals USA, Inc., #237 MOTION for Pro Hac Vice Appearance of Attorney Corey Weinstein filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 5/6/21. (ntl)
May 5, 2021 Filing 241 Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Technology Tutorial. (Phillips, John)
May 5, 2021 Filing 240 Letter to The Honorable Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiff's Technology Tutorial. (Silver, Daniel)
May 5, 2021 Filing 239 MOTION for Pro Hac Vice Appearance of Attorney Mark C. McLennan - filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan)
May 5, 2021 Filing 238 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso regarding Defendants' Discovery Dispute Letter Concerning the Deposition of Plaintiff's Expert Dr. Klibanov. (Gattuso, Dominick)
May 4, 2021 Filing 237 MOTION for Pro Hac Vice Appearance of Attorney Corey Weinstein - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Certification of Corey Weinstein, Esq., #2 Text of Proposed Order)(Seaman, John)
May 4, 2021 Opinion or Order Filing 236 ORAL ORDER: Having been advised by Plaintiff and Defendants of their inability to resolve a discovery matter (see D.I. 234), IT IS HEREBY ORDERED that not later than May 5, 2021 at 10:00 a.m., any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than May 6, 2021 at 10:00 a.m., any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. A teleconference to address the dispute, if necessary, will be held on May 10 at 10:15 a.m. The parties and any interested member of the public can access the teleconference by dialing 877-336-1829 and using the access code 1408971. ORDERED by Judge Leonard P. Stark on 5/4/21. (ntl)
May 3, 2021 Filing 235 NOTICE requesting Clerk to remove Karen L. Carroll as co-counsel. Reason for request: no longer with the firm of Parker Poe Adams & Bernstein LLP. (Palapura, Bindu)
April 29, 2021 Filing 234 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Request Discovery Hearing. (Gattuso, Dominick)
April 29, 2021 Filing 233 NOTICE OF SERVICE of (1) Novartis's Reply Claim Construction Brief, (2) Declaration of Laura K. Fishwick, Esq., and (3) Reply Declaration of Alexander M. Klibanov, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
April 27, 2021 Filing 232 NOTICE of Change of Address by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Torrent Pharmaceuticals Ltd., Hetero USA Inc. (Ormerod, Eve)
April 21, 2021 Filing 231 NOTICE OF SERVICE of Novartis's Objections to Defendants' Notice of Deposition of Alexander M. Klibanov, Ph.D., Pursuant to Fed. R. Civ. P. 30(b)(1) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
April 16, 2021 Filing 230 NOTICE OF SERVICE of DEFENDANT MYLAN PHARMACEUTICALS PRODUCTION OF DOCUMENTS LABELED MYLAN_SACVAL_00061802-MYLAN_SACVAL_00158295 [HIGHLY CONFIDENTIAL OUTSIDE ATTORNEY'S EYES ONLY] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
April 16, 2021 Opinion or Order SO ORDERED, re (228 in 1:20-md-02930-LPS, 77 in 1:19-cv-02021-LPS, 55 in 1:20-cv-00074-LPS, 220 in 1:19-cv-01979-LPS) STIPULATION TO EXTEND TIME for Substantial Completion of Document Production to May 14, 2021 filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 4/16/21. Associated Cases: 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:20-cv-00074-LPS, 1:20-md-02930-LPS (ntl)
April 14, 2021 Filing 229 NOTICE OF SERVICE of documents in response to Request for Productions identified by bates range DRL-SV00037475 DRL-SV00166523 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
April 14, 2021 Filing 228 STIPULATION TO EXTEND TIME for Substantial Completion of Document Production to May 14, 2021 - filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Ormerod, Eve)
April 5, 2021 Filing 227 NOTICE OF SERVICE of Crystal Pharmaceutical (Suzhou) Co., Ltd.'s production of documents labeled CRYSAVA033035 CRYSAVA090043 [HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
March 31, 2021 Filing 226 NOTICE OF SERVICE of (i) Defendants' Joint Responsive Claim Construction Brief [with exhibits]; and, (ii) Declaration of Raymond Butcher, Ph.D. [with exhibits] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
March 30, 2021 Filing 225 NOTICE to Take Deposition of Alexander M. Klibanov, Ph.D., on May 5, 2021 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
March 16, 2021 Opinion or Order SO ORDERED, re (223 in 1:20-md-02930-LPS, 52 in 1:20-cv-00074-LPS, 74 in 1:19-cv-02021-LPS, 103 in 1:20-cv-00445-LPS, 215 in 1:19-cv-01979-LPS, 122 in 1:19-cv-02053-LPS, 55 in 1:20-cv-00415-LPS) STIPULATION and [Proposed] Order Extending Deadline to Amend the Pleadings; (51 in 1:20-cv-00074-LPS, 121 in 1:19-cv-02053-LPS, 213 in 1:19-cv-01979-LPS, 54 in 1:20-cv-00415-LPS, 73 in 1:19-cv-02021-LPS, 102 in 1:20-cv-00445-LPS, 221 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Extending Time to Meet and Confer Regarding Depositions. Signed by Judge Leonard P. Stark on 3/15/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl)
March 15, 2021 Filing 224 NOTICE OF SERVICE of Defendants Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Inc., and Lupin Pharmaceuticals, Inc.s Supplemental Objections and Responses to Plaintiffs Second Set of Interrogatories to Lupin (Nos. 3-5) filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
March 12, 2021 Filing 223 STIPULATION and [Proposed] Order Extending Deadline to Amend the Pleadings re (45 in 1:19-cv-02021-LPS, 33 in 1:20-cv-00415-LPS, 102 in 1:20-md-02930-LPS, 29 in 1:20-cv-00074-LPS, 78 in 1:19-cv-02053-LPS, 137 in 1:19-cv-01979-LPS, 74 in 1:20-cv-00445-LPS) Scheduling Order,, by Mylan Pharmaceuticals Inc.. (Palapura, Bindu)
March 12, 2021 Filing 222 NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants Aurobindo Pharma Limited's and Aurobindo Pharma USA, Inc.'s First Set of Individual Interrogatories (Nos. 1-6) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
March 11, 2021 Filing 221 STIPULATION and [Proposed] Order Extending Time to Meet and Confer Regarding Depositions by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
March 8, 2021 Filing 220 REDACTED VERSION of (215 in 1:20-md-02930-LPS, 207 in 1:19-cv-01979-LPS) MOTION to Redact (205 in 1:19-cv-01979-LPS, 212 in 1:20-md-02930-LPS) Transcript by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.. (Attachments: #1 Exhibit A, #2 Exhibit B)(Ormerod, Eve)
March 5, 2021 Filing 219 Redaction of #212 Transcript. (bpg)
March 4, 2021 Opinion or Order Filing 218 ORDER re (215 in 1:20-md-02930-LPS, 207 in 1:19-cv-01979-LPS) MOTION to Redact (205 in 1:19-cv-01979-LPS, 212 in 1:20-md-02930-LPS) Transcript filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. Signed by Judge Leonard P. Stark on 3/3/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
March 4, 2021 Filing 217 NOTICE OF SERVICE of (1) Novartiss Opening Claim Construction Brief and (2) Declaration of Alexander M. Klibanov filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
March 4, 2021 Opinion or Order SO ORDERED, re (213 in 1:20-md-02930-LPS, 206 in 1:19-cv-01979-LPS, 52 in 1:20-cv-00415-LPS, 99 in 1:20-cv-00445-LPS, 71 in 1:19-cv-02021-LPS, 119 in 1:19-cv-02053-LPS, 49 in 1:20-cv-00074-LPS) STIPULATION TO EXTEND TIME for the substantial completion of document production to April 14, 2021 filed by Biocon Limited, Biocon Pharma, Inc., Alkem Laboratories Ltd., Biocon Pharma Limited, Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. Signed by Judge Leonard P. Stark on 3/3/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl)
March 1, 2021 Filing 216 PROPOSED ORDER re (215 in 1:20-md-02930-LPS, 207 in 1:19-cv-01979-LPS) MOTION to Redact (205 in 1:19-cv-01979-LPS, 212 in 1:20-md-02930-LPS) Transcript from February 25, 2021 Telephonic Hearing by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve)
March 1, 2021 Filing 215 [SEALED] MOTION to Redact (205 in 1:19-cv-01979-LPS, 212 in 1:20-md-02930-LPS) Transcript - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.. (Attachments: #1 Exhibit A, #2 Exhibit B)(Ormerod, Eve)
March 1, 2021 Filing 214 NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendant Mylan Pharmaceuticals Inc.'s First Set of Individual Interrogatories (Nos. 1-4) and (2) Novartis's Objections and Responses to Defendant Mylan Pharmaceuticals Inc.'s First Set of Individual Requests for Production (Nos. 1-2) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
March 1, 2021 Filing 213 STIPULATION TO EXTEND TIME for the substantial completion of document production to April 14, 2021 - filed by Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Dorsney, Kenneth)
March 1, 2021 Filing 212 [SEALED] Transcript of Telephonic Oral Argument held on February 25, 2021 before Chief Judge Leonard P. Stark. (bpg)
March 1, 2021 Filing 211 Official Transcript of Telephonic Oral Argument held on February 25, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. (bpg) Modified on 3/4/2021 (ntl). Modified on 3/5/2021 (ntl).
February 26, 2021 Filing 210 NOTICE requesting Clerk to remove Micheal L. Binns as co-counsel. Reason for request: no longer with the firm of Parker Poe Adams & Bernstein LLP. (Palapura, Bindu) Modified on 2/26/2021 (amf).
February 23, 2021 Filing 209 NOTICE OF SERVICE of Defendants Objections and Responses to Plaintiffs First Set of Common Interrogatories to Defendants (as to all Defendants) filed by Cadila Healthcare Ltd., Laurus Generics Inc., Laurus Labs Limited, Novugen Pharma (Malaysia) Sdn. Bhd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
February 22, 2021 Opinion or Order Filing 208 ORAL ORDER: Having considered Defendants' requests to seal confidential portions of the upcoming February 25, 2021 hearing and corresponding transcript (D.I. 197, 201), which is unopposed by Plaintiff, IT IS HEREBY ORDERED that Defendants' request is GRANTED. Accordingly, Defendants shall provide the Court and Plaintiff's counsel (as well as other defendants' outside counsel) with the credentials for a telephone line, to be used for discussion of confidential issues, via email no later than 4:00 p.m. the day before the hearing. The parties shall submit their proposed transcript redactions within two (2) business days of receipt of the transcript. ORDERED by Judge Leonard P. Stark on 2/22/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
February 22, 2021 Filing 207 Letter to The Honorable Leonard P. Stark from Eve H. Ormerod regarding Request to Seal Portions of the February 25, 2021 Telephonic Hearing - re (197 in 1:19-cv-01979-LPS, 203 in 1:20-md-02930-LPS) Letter. (Ormerod, Eve)
February 17, 2021 Filing 206 APPENDIX re (96 in 1:20-cv-00445-LPS, 117 in 1:19-cv-02053-LPS, 199 in 1:19-cv-01979-LPS, 69 in 1:19-cv-02021-LPS, 50 in 1:20-cv-00415-LPS, 205 in 1:20-md-02930-LPS, 47 in 1:20-cv-00074-LPS) Claim Construction Chart by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-17, #2 Exhibit 18-25, #3 Exhibit 26-36)(Silver, Daniel)
February 17, 2021 Filing 205 CLAIM Construction Chart by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
February 16, 2021 Filing 204 NOTICE OF SERVICE of Novartis's Objections and Responses to Defendant Crystal Pharma's First Set of Individual Interrogatories (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
February 16, 2021 Opinion or Order SO ORDERED, re (68 in 1:19-cv-02021-LPS, 196 in 1:19-cv-01979-LPS, 115 in 1:19-cv-02053-LPS, 201 in 1:20-md-02930-LPS, 49 in 1:20-cv-00415-LPS, 95 in 1:20-cv-00445-LPS, 46 in 1:20-cv-00074-LPS) STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Joint Claim Construction Chart to February 17, 2021 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/16/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl)
February 12, 2021 Filing 203 Letter to The Honorable Leonard P. Stark from Eve H. Ormerod regarding request to seal portions of upcoming hearing on February 25, 2021. (Ormerod, Eve)
February 12, 2021 Filing 202 NOTICE of of Change of Law Firm Affiliation by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. (Stamoulis, Stamatios)
February 12, 2021 Filing 201 STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Joint Claim Construction Chart to February 17, 2021 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
February 1, 2021 Filing 200 NOTICE OF SERVICE of Novartis's Rebuttal Proposed Constructions of Claim Terms and Intrinsic Evidence filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
January 29, 2021 Filing 199 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s First Set Of Individual Interrogatories (Nos. 1-4) To Plaintiff Novartis Pharmaceuticals Corporation [Highly Confidential Attorneys' Eyes Only]; and Defendant Mylan Pharmaceuticals Inc.'s First Set Of Individual Requests For Production (Nos. 1-2) To Plaintiff Novartis Pharmaceuticals Corporation [Highly Confidential Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
January 29, 2021 Opinion or Order SO ORDERED, re (198 in 1:20-md-02930-LPS) (44 in 1:20-cv-00074-LPS, 92 in 1:20-cv-00445-LPS, 47 in 1:20-cv-00415-LPS, 113 in 1:19-cv-02053-LPS, 66 in 1:19-cv-02021-LPS, 194 in 1:19-cv-01979-LPS) STIPULATION TO EXTEND TIME for completion of production of documents to March 15, 2021 filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 1/28/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl)
January 27, 2021 Filing 198 STIPULATION TO EXTEND TIME for completion of production of documents to March 15, 2021 - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Seaman, John)
January 27, 2021 Filing 197 NOTICE OF SERVICE of Aurobindo's First Set of Interrogatories to Plaintiff (Nos. 1-6) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth)
January 22, 2021 Filing 196 NOTICE OF SERVICE of (1) Novartis's First Supplemental Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-7) and (2) Novartis's First Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
January 19, 2021 Filing 195 NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.s First Set of Individual Interrogatories (Nos. 1-3) to Plaintiff Novartis Pharmaceuticals Corporation filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
January 14, 2021 Filing 194 NOTICE of Change of Address of Certain Pro Hac Vice Counsel by Mylan Pharmaceuticals Inc. (Moore, David)
January 13, 2021 Filing 193 NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s First Supplemental Responses and Objections to Novartis's Second Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 3-5) [Highly Confidential-Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
January 11, 2021 Filing 192 NOTICE requesting Clerk to remove Peter J. Fallon as co-counsel. Reason for request: retired from Locke Lord. (Poff, Adam)
January 9, 2021 Filing 191 NOTICE OF SERVICE of Defendants Preliminary Claim Constructions and Supporting Evidence filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
January 7, 2021 Filing 190 NOTICE OF SERVICE of Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s First Supplemental Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
January 6, 2021 Filing 189 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's First Supplemental Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
January 5, 2021 Filing 188 NOTICE OF SERVICE of Teva's First Supplemental Responses to Novartis' Second Set of Interrogatories filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
January 5, 2021 Opinion or Order Filing 187 ORAL ORDER: IT IS HEREBY ORDERED that the Court will hear argument by teleconference on the motion for judgment on the pleadings on February 25, 2021 beginning at 11:00 a.m. Each side will be allocated up to forty-five (45) minutes to present its argument. Any party wishing to refer to slides or other materials shall provide a copy to the Court no later than 4:00 p.m. the day before the hearing. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. ORDERED by Judge Leonard P. Stark on 1/5/21. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
December 18, 2020 Pro Hac Vice Attorney Jane S. Berman for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS. (kmd)
December 17, 2020 Filing 186 MOTION for Pro Hac Vice Appearance of Attorney Jane S. Berman - filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth)
December 17, 2020 Opinion or Order SO ORDERED, re (187 in 1:19-cv-01979-LPS, 186 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Jane S. Berman filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 12/17/20. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
December 10, 2020 Filing 185 NOTICE of Withdrawal of Tracey E. Timlin by Mylan Pharmaceuticals Inc. (Moore, David)
December 8, 2020 Filing 184 NOTICE OF SERVICE of Crystal Pharmaceutical (Suzhou) Co., Ltd.'s production of documents labeled CRYSAVA016058 - CRYSAVA033034 [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
December 8, 2020 Filing 183 NOTICE OF SERVICE of Defendants' Joint Initial Invalidity Contentions Under Local Patent Rules filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
December 7, 2020 Filing 182 NOTICE OF SERVICE of Defendants' Joint Invalidity Contentions filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Dr. Reddys Laboratories, Inc., Hetero USA Inc..(Ormerod, Eve)
December 7, 2020 Filing 181 NOTICE OF SERVICE of Defendants' Joint Initial Invalidity Contentions Under Local Patent Rules filed by Mylan Pharmaceuticals Inc..(Moore, David)
December 2, 2020 Pro Hac Vice Attorney Steven J. Moore for Aurobindo Pharma USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 19-cv-01979-LPS, 20-md-02930-LPS (myr)
November 25, 2020 Filing 180 Amended Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc.. (Palapura, Bindu)
November 25, 2020 Opinion or Order SO ORDERED, re (184 in 1:19-cv-01979-LPS, 179 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and Attorney James E. Nealon filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. Signed by Judge Leonard P. Stark on 11/25/20. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
November 24, 2020 Filing 179 MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and Attorney James E. Nealon - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Dorsney, Kenneth)
November 24, 2020 Filing 178 NOTICE OF SERVICE of Novartis's Objections and Responses to Torrent's First Set of Individual Interrogatories (Nos. 1-4) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
November 19, 2020 Filing 177 NOTICE OF SERVICE of Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
November 19, 2020 Filing 176 NOTICE OF SERVICE of Response to Plaintiffs Second Set of Interrogatories (Nos. 3-5) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios)
November 19, 2020 Filing 175 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Poff, Adam)
November 19, 2020 Filing 174 NOTICE OF SERVICE of Defendants Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Inc., and Lupin Pharmaceuticals, Inc.'s Objections and Responses to Plaintiff's Second Set of Interrogatories to Lupin (Nos. 3-5) filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
November 19, 2020 Filing 173 NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Answers to Plaintiff Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Haney, Megan)
November 19, 2020 Filing 172 NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's Second Set Of Interrogatories To Mylan Pharmaceuticals Inc. (Nos. 3-5) [Highly Confidential Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
November 19, 2020 Filing 171 NOTICE OF SERVICE of 1) Torrent's Objections and Responses to Plaintiff's Second Set of Interrogatories (Nos. 3-5) and 2) Hetero's Objections and Responses to Plaintiff's Second Set of Interrogatories (Nos. 3-5) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc..(Ormerod, Eve)
November 19, 2020 Filing 170 NOTICE OF SERVICE of Alembic's Objections and Responses to Plaintiff's Second Set of Interrogatories (Nos. 3-5) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Ormerod, Eve)
November 19, 2020 Filing 169 NOTICE OF SERVICE of Biocon's response to Plaintiff's Second Set of Interrogatories (Nos. 3-5) filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Dorsney, Kenneth)
November 19, 2020 Filing 168 NOTICE OF SERVICE of Aurobindo's response to Plaintiff's Second Set of Interrogatories (Nos. 3-5) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth)
November 19, 2020 Filing 167 NOTICE OF SERVICE of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John)
November 19, 2020 Filing 166 NOTICE OF SERVICE of Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth)
November 19, 2020 Filing 165 NOTICE OF SERVICE of Defendants Laurus Labs Limited and Laurus Generics Inc.'s Responses and Objections to Plaintiff's Second Set of Interrogatories (Nos. 3-5) filed by Laurus Generics Inc., Laurus Labs Limited.(Poff, Adam)
November 19, 2020 Filing 164 NOTICE OF SERVICE of Responses to second set of interrogatories filed by Alkem Laboratories Ltd..(Dorsney, Kenneth)
November 19, 2020 Filing 163 NOTICE OF SERVICE of Crystal Pharmaceutical (Suzhou) Co., Ltd.s Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
November 18, 2020 Filing 162 NOTICE OF SERVICE of (1) Teva's Responses to Novartis's Second Set of Interrogatories filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
November 16, 2020 Filing 161 NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-7) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
November 12, 2020 Filing 160 NOTICE OF SERVICE of Crystal Pharmaceutical (Suzhou) Co., Ltd.'s production of documents labeled CRYSAVA013122 - CRYSAVA015957 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
November 5, 2020 Filing 159 NOTICE OF SERVICE of Response to Plaintiffs First Set of Interrogatories (Nos. 1-2) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios)
November 4, 2020 Filing 158 NOTICE OF SUBSTITUTION OF COUNSEL re Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.: Entry of appearance of attorney Eve H. Ormerod. Attorney Helena C. Rychlicki terminated. (Ormerod, Eve)
October 26, 2020 Opinion or Order SO ORDERED, re (159 in 1:19-cv-01979-LPS, 139 in 1:20-md-02930-LPS) Stipulation of Dismissal of Biocon's Counterclaim Counts VII, VIII, IX and X filed by Biocon Limited, Biocon Pharma, Inc., Biocon Pharma Limited. Signed by Judge Leonard P. Stark on 10/23/20. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS (ntl)
October 22, 2020 Filing 157 NOTICE OF SERVICE of Objections and Responses to Novartiss First Set of Interrogatories (Nos. 1-2) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
October 22, 2020 Filing 156 NOTICE OF SERVICE of Objections and Responses to First Set of Interrogatories (Nos. 1-2) filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
October 22, 2020 Filing 155 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's First Set of Interrogatories (Nos. 1-2) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
October 22, 2020 Filing 154 NOTICE OF SERVICE of Defendants Laurus Labs Limited and Laurus Generics Inc.'s Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-2) filed by Laurus Generics Inc., Laurus Labs Limited.(Swadley, Beth)
October 22, 2020 Filing 153 NOTICE OF SERVICE of Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss First Set of Interrogatories (Nos. 1 and 2) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth)
October 22, 2020 Filing 152 NOTICE OF SERVICE of Alkem's Response to Plaintiff's First Set of Interrogatories (Nos. 1-2) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth)
October 22, 2020 Filing 151 NOTICE OF SERVICE of Torrent's First Set of Interrogatories (Nos. 1-4) to Plaintiff Novartis Pharmaceuticals Corporation filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd..(Belgam, Neal)
October 22, 2020 Filing 150 NOTICE OF SERVICE of Crystal Pharmaceutical (Suzhou) Co., Ltd.s [Confidential] Responses to Novartiss First Set of Interrogatories (Nos. 1-2) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
October 22, 2020 Filing 149 NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Answers to Plaintiff Novartis's First Set of Interrogatories (Nos. 1-2) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Haney, Megan)
October 22, 2020 Filing 148 NOTICE OF SERVICE of Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's First Set of Interrogatories (Nos. 1-2) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Rychlicki, Helena)
October 22, 2020 Filing 147 NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Responses and Objections to Novartis's First Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 1-2) [Highly Confidential-Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
October 22, 2020 Filing 146 NOTICE OF SERVICE of Biocon's Responses and Objections to Novartis' First Set of Interrogatories (Nos. 1-2) filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Dorsney, Kenneth)
October 22, 2020 Filing 145 NOTICE OF SERVICE of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's First Set of Interrogatories (Nos. 1-2) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John)
October 22, 2020 Filing 144 NOTICE OF SERVICE of 1) Torrent's Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-2) and 2) Hetero's Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-2) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc..(Belgam, Neal)
October 22, 2020 Filing 143 NOTICE OF SERVICE of Aurobindo's response to Plaintiff's First Set of Interrogatories (Nos. 1-2) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth)
October 22, 2020 Filing 142 NOTICE OF SERVICE of Teva's Responses to Novartis's First Set of Interrogatories filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
October 21, 2020 Filing 141 NOTICE OF SERVICE of (1) Novartiss Second Set of Interrogatories to Defendants (Nos. 3-5) and (2) Plaintiffs Initial Infringement Chart Against Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
October 20, 2020 Filing 140 NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-108) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
October 19, 2020 Filing 139 STIPULATION of Dismissal of Biocon's Counterclaim Counts VII, VIII, IX and X by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Dorsney, Kenneth)
October 16, 2020 Filing 138 NOTICE OF SERVICE of Response to Plaintiffs Fourth Set of Requests for the Production of Documents and Things Nos. (75-80) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios)
October 16, 2020 Pro Hac Vice Attorney Philip Y. Kouyoumdjian for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (myr)
October 16, 2020 Opinion or Order SO ORDERED, re (136 in 1:20-md-02930-LPS, 157 in 1:19-cv-01979-LPS) MOTION for Pro Hac Vice Appearance of Attorney Philip Y. Kouyoumdjian filed by Alkem Laboratories Ltd.. Signed by Judge Leonard P. Stark on 10/16/20. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS(ntl)
October 15, 2020 Filing 137 NOTICE OF SERVICE of Defendants First Set of Interrogatories (Nos. 1-7) to Plaintiff Novartis Pharmaceuticals Corporation filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
October 15, 2020 Filing 136 MOTION for Pro Hac Vice Appearance of Attorney Philip Y. Kouyoumdjian - filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth)
October 9, 2020 Filing 135 NOTICE OF SERVICE of (1) MSN Pharmaceuticals Inc., MSN Laboratories Private Limiteds and MSN Life Sciences Private Limiteds Response to Plaintiffs Third Set of Requests for the Production of Documents and Things and (2) MSN Pharmaceuticals Inc., MSN Laboratories Private Limiteds and MSN Life Sciences Private Limiteds Response to Plaintiffs Second Set of Requests for the Production of Documents and Things filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios)
October 6, 2020 Pro Hac Vice Attorneys Michael J. Gaertner, James T. Peterka, Nina Vachhani for Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS(kmd)
October 5, 2020 Filing 134 NOTICE OF SERVICE of (1) Aurobindo's Responses to Plaintiff's Second Set of Requests for Production (Nos. 15-61); (2) Aurobindo's Responses to Plaintiff's Third Set of Requests for Production (Nos. 62-74) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth)
October 5, 2020 Filing 133 NOTICE OF SERVICE of 1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Second Set of Requests to Zydus for the Production of Documents and Things (Nos. 15-61); and 2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Third Set of Requests to Zydus for the Production of Documents and Things (Nos. 62 - 74); filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
October 5, 2020 Filing 132 NOTICE OF SERVICE of 1) Defendant Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Second Set of Requests for the Production of Documents and Things (Nos. 21-67); and 2) Defendant Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Third Set of Requests for the Production of Documents and Things (Nos. 68-86) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth)
October 5, 2020 Filing 131 NOTICE OF SERVICE of 1) Defendants Laurus Labs Ltd. and Laurus Generics Inc.s Responses and Objections to Plaintiffs Second Set of Requests for Production (Nos. 15-61); and 2) Defendants Laurus Labs Ltd. and Laurus Generics Inc.s Responses and Objections to Plaintiffs Third Set of Requests for Production (Nos. 62-74) filed by Laurus Generics Inc., Laurus Labs Limited.(Swadley, Beth)
October 5, 2020 Filing 130 NOTICE OF SERVICE of 1) Responses and Objections to Plaintiff's Second Set of Requests for the Production of Documents and Things (Nos. 15-61) and 2) Responses and Objections to Plaintiff's Third Set of Requests for the Production of Documents and Things (Nos. 62-74) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc..(Ormerod, Eve)
October 2, 2020 Filing 129 NOTICE OF SERVICE of (1) Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss Third Set of Requests for the Production of Documents and Things (Nos. 62-74) and (2) Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss Second Set of Requests for the Production of Documents and Things (Nos. 15-61) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
October 2, 2020 Filing 128 NOTICE OF SERVICE of (1) Alkem's response to Plaintiff's Second Set of Requests for Production (Nos. 15-61); and (2) Alkem's response to Plaintiff's Third Set of Requests for Production (Nos. 62-74) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth)
October 2, 2020 Filing 127 NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's Second Set Of Requests To Mylan Pharmaceuticals Inc. For The Production Of Documents And Things (Nos. 15-61) [Highly Confidential Attorneys' Eyes Only]; Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's Third Set Of Requests To Mylan Pharmaceuticals Inc. For The Production Of Documents And Things (Nos. 62-74) [Highly Confidential Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Timlin, Tracey)
October 2, 2020 Filing 126 NOTICE OF SERVICE of (1) Nanjing Noratech Pharmaceutical Co., Limited Responses to Novartis's Second Set of Requests for the Production of Documents and Things (Nos. 17-63); and (2) Nanjiing Noratech Pharmaceutical Co., Limited Responses to Novartis's Third Set of Requests for the Production of Documents and Things (Nos. 64-81) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Haney, Megan)
October 2, 2020 Filing 125 NOTICE OF SERVICE of Defendants (1) Objections and Responses to Plaintiff's Second Set of Requests for the Production of Documents and Things (Nos. 35-105) and (2) Objections and Respones to Plaintiff's Third Set of Requests for the Production and Things (Nos. 106-137) filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
October 2, 2020 Filing 124 NOTICE OF SERVICE of Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's Second Set of Requests for the Production of Documents and Things (Nos. 15-61) and Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's Third Set of Requests for the Production of Documents and Things (Nos. 62-74) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Rychlicki, Helena)
October 2, 2020 Filing 123 NOTICE OF SERVICE of (i) Crystal Pharmaceutical's Responses to Novartis's Second Set of Request for Production (Nos. 15-61) and (ii) Responses to Novartis's Third Set of Requests for Production (Nos. 62-74) [CONFIDENTIAL filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
October 2, 2020 Filing 122 NOTICE OF SERVICE of (1) Biocon's Responses to Plaintiff's Second Set of Requests for Production (Nos.19-65); (2) Biocon's Responses to Plaintiff's Third Set of Requests for Production (Nos. 66-84) filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Dorsney, Kenneth)
October 2, 2020 Filing 121 NOTICE OF SERVICE of 1) Teva's Responses to Novartis's Second Set of Requests for the Production of Documents and Things and 2) Teva's Responses to Novartis's Third Set of Requests for the Production of Documents and Things filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
October 2, 2020 Filing 120 NOTICE OF SERVICE of (i) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's Second Set of Requests for Production (Nos. 15-61) and (ii) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Highly Confidential Objections and Responses to Novartis's Third Set of Requests for Production (Nos. 62-74) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John)
October 1, 2020 Opinion or Order SO ORDERED, re (84 in 1:19-cv-02053-LPS, 119 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Michael J. Gaertner, James T. Peterka, and Nina Vachhani filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 10/1/20. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
September 30, 2020 Filing 119 MOTION for Pro Hac Vice Appearance of Attorney Michael J. Gaertner, James T. Peterka, and Nina Vachhani - filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Swadley, Beth)
September 28, 2020 Filing 118 NOTICE OF SERVICE of Objections and Responses to Novartiss First Set of Requests for the Production of Documents and Things (Nos. 1-14) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
September 28, 2020 Filing 117 NOTICE OF SERVICE of Response to Plaintiffs First Set of Requests for the Production of Documents and Things filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios)
September 28, 2020 Filing 116 NOTICE OF SERVICE of Defendants Laurus Labs Ltd. and Laurus Generics Inc.s Responses and Objections to Plaintiffs First Set of Requests for Production (Nos. 1-14) filed by Laurus Generics Inc., Laurus Labs Limited.(Swadley, Beth)
September 28, 2020 Filing 115 NOTICE OF SERVICE of Novugen Pharma (Malaysia) Sdn. Bhd.'s Objections and Responses to Novartis's First Set of Requests for the Production of Documents and Things (Nos. 1-20) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth)
September 28, 2020 Filing 114 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's First Set of Requests for the Production of Documents and Things (Nos. 1-14) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
September 28, 2020 Filing 113 NOTICE OF SERVICE of Alembic Pharmaceuticals Limited 's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's First Set of Requests for the Production of Documents and Things (Nos. 1-14) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Rychlicki, Helena)
September 28, 2020 Filing 112 NOTICE OF SERVICE of Responses to Novartis's First Set of Requests for Production of Documents and Things (Nos. 1-14) [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 28, 2020 Filing 111 NOTICE OF SERVICE of Objections and Responses to Plaintiff's First Set of Requests for the Production of Documents and Things (Nos. 1-34) filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
September 28, 2020 Filing 110 NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited Responses to Novartis's First Set of Requests for the Production of Documents and Things filed by Nanjing Noratech Pharmaceutical Co., Limited.(Haney, Megan)
September 28, 2020 Filing 109 NOTICE OF SERVICE of Aurobindo's response to Plaintiffs' First Set of Requests for Production (Nos. 1-14) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth)
September 28, 2020 Filing 108 NOTICE OF SERVICE of Tevas Responses to Novartis's First Set of Requests for the Production of Documents and Things filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan)
September 28, 2020 Filing 107 NOTICE OF SERVICE of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's First Set of Requests for Production (Nos. 1-14) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John)
September 28, 2020 Filing 106 NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Responses and Objections to Novartis's First Set of Requests to Mylan Pharmaceuticals Inc. for the Production of Documents and Things [Highly Confidential-Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
September 28, 2020 Filing 105 NOTICE OF SERVICE of Alkem's response to Plaintiffs' First Set of Requests for Production (Nos. 1-14) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth)
September 25, 2020 Filing 104 NOTICE OF SERVICE of Biocon's response to Plaintiffs' First Set of Requests for Production (Nos. 1-18) filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Dorsney, Kenneth)
September 22, 2020 Filing 103 NOTICE OF SERVICE of Novartis's First Set of Interrogatories to Defendants (Nos. 1-2) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
September 18, 2020 Opinion or Order Filing 102 SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Fact Discovery completed by 10/20/2021. Status Report due by 11/3/2021. Joint Claim Construction Brief due by 5/21/2021. A Markman Hearing is set for 6/7/2021 at 12:30 PM in Courtroom 6B before Judge Leonard P. Stark. A Final Pretrial Conference is set for 8/26/2022 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. A 12-day Bench Trial is set for 9/8/2022 at 08:30 AM in Courtroom 6B before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 9/14/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl)
September 18, 2020 Filing 101 NOTICE OF SERVICE of Objections and Responses to Plaintiff's First Set of Requests for Production of Documents and Things (Nos. 1-14) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd..(Ormerod, Eve)
September 18, 2020 Opinion or Order SO ORDERED, re (24 in 1:20-cv-00074-LPS, 80 in 1:20-md-02930-LPS, 67 in 1:19-cv-02053-LPS, 40 in 1:19-cv-02021-LPS, 68 in 1:20-cv-00445-LPS, 122 in 1:19-cv-01979-LPS, 26 in 1:20-cv-00415-LPS) STIPULATED PROTECTIVE ORDER. Signed by Judge Leonard P. Stark on 9/14/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl)
September 17, 2020 Filing 100 NOTICE OF SERVICE of Objections and Responses to Plaintiff's First Set of Requests for Production of Documents and Things (Nos. 1-14) filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc..(Ormerod, Eve)
September 17, 2020 Filing 99 NOTICE OF SERVICE of Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-108) to Plaintiff Novartis Pharmaceuticals Corporation filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
September 16, 2020 Filing 98 NOTICE OF SERVICE of Novartiss Fourth Set of Requests to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, & MSN Life Sciences Private Limited for the Production of Documents and Things (Nos. 75-78) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
September 16, 2020 Opinion or Order SO ORDERED, re #97 MOTION for Pro Hac Vice Appearance of Attorney Catherine R. Gourash filed by Lupin Inc., Lupin Limited, Lupin Atlantis Holdings, S.A., Lupin Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 9/16/20. (ntl)
September 14, 2020 Filing 97 MOTION for Pro Hac Vice Appearance of Attorney Catherine R. Gourash - filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc.. (Cottrell, Frederick)
September 11, 2020 Filing 96 PROPOSED ORDER Scheduling by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
September 9, 2020 Opinion or Order SO ORDERED, re (42 in 1:19-cv-02021-LPS, 71 in 1:20-cv-00445-LPS, 73 in 1:19-cv-02053-LPS, 132 in 1:19-cv-01979-LPS, 26 in 1:20-cv-00074-LPS, 29 in 1:20-cv-00415-LPS, 95 in 1:20-md-02930-LPS) STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Revised Proposed Scheduling Order to September 11, 2020 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 9/8/20. Associated Cases: 1:20-md-02930-LPS et al. (ntl)
September 4, 2020 Filing 95 STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Revised Proposed Scheduling Order to September 11, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
September 3, 2020 Filing 94 NOTICE OF SERVICE of correspondence pursuant to the Court's August 24, 2020 Order regarding Drug Master files and samples filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth)
September 3, 2020 Filing 93 NOTICE OF SERVICE of correspondence regarding Drug Master files and samples filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
September 3, 2020 Filing 92 NOTICE OF SERVICE of (1) Novartiss Second Set of Requests to Defendants for the Production of Documents and Things ; and (2) Novartiss Third Set of Requests to Defendants for the Production of Documents and Things filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
September 3, 2020 CORRECTING ENTRY: Notice of Service was removed from the docket per request of counsel (SEE D.I. 127 in 19-1979 and D.I. 88 in 20md2930). Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
September 1, 2020 Filing 91 NOTICE OF SERVICE of Defendants Laurus Labs Ltd. and Laurus Generics Inc.'s correspondence pursuant to the Court's August 24, 2020 Order regarding Drug Master files and samples filed by Laurus Generics Inc., Laurus Labs Limited.(Swadley, Beth)
September 1, 2020 Filing 90 NOTICE OF SERVICE of Teva Pharmaceutical USA, Inc.s Correspondence pursuant to the August 24, 2020 Oral Order regarding Drug Master Files, API and Product Samples filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen)
September 1, 2020 Filing 89 NOTICE OF SERVICE of Noratech's Disclosure Pursuant to the August 24, 2020 Oral Order filed by Nanjing Noratech Pharmaceutical Co., Limited.(Haney, Megan)
September 1, 2020 Filing 87 NOTICE OF SERVICE of notice regarding Drug Master File and Samples filed by Alkem Laboratories Ltd..(Dorsney, Kenneth)
September 1, 2020 Filing 86 NOTICE OF SERVICE of notice regarding Drug Master File and Samples filed by Biocon Limited, Biocon Pharma Limited.(Dorsney, Kenneth)
September 1, 2020 Filing 85 NOTICE OF SERVICE of Correspondence, Pursuant to the Courts August 24, 2020 Order, Regarding Drug Master Files and Samples re 75 Order,, Telephone Conference filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Rychlicki, Helena)
September 1, 2020 Filing 84 NOTICE OF SERVICE of Disclosure Pursuant to Court's August 24, 2020 Oral Order filed by Mylan Pharmaceuticals Inc..(Moore, David)
August 31, 2020 Filing 83 NOTICE OF SERVICE of correspondence pursuant to the Courts August 24, 2020 Order regarding Drug Master Files and samples filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
August 31, 2020 Filing 82 NOTICE OF SERVICE of Correspondence Pursuant to Court's August 24, 2020 Order regarding Drug Master Files and Samples filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
August 31, 2020 Filing 81 NOTICE OF SERVICE of Letter Regarding the Drug Master File for Torrent and Hetero's API and Drug or Product Samples filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc..(Ormerod, Eve)
August 31, 2020 Filing 80 PROPOSED ORDER Stipulated Protective Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
August 31, 2020 Filing 79 NOTICE OF SERVICE of Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Notice Pursuant to August 24, 2020 Order filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John)
August 31, 2020 Filing 78 NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd. served a letter regarding the Drug Master File for Crystals API and its drug or product samples filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
August 28, 2020 Filing 77 NOTICE OF SERVICE of Novartis's First Set of Requests to Defendants for the Production of Documents and Things filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
August 27, 2020 Filing 76 Official Transcript of Telephone Conference held on August 24, 2020 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, e-mail: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/17/2020. Redacted Transcript Deadline set for 9/28/2020. Release of Transcript Restriction set for 11/25/2020. (bpg)
August 25, 2020 Opinion or Order Filing 75 ORAL ORDER: For the reasons stated during the teleconference on August 24, 2020, IT IS HEREBY ORDERED THAT a revised version of the proposed protective order is due on August 31, 2020, and a revised version of the proposed scheduling order is due on September 4, 2020, both incorporating the dates and decisions the Court announced during the hearing, including that the bench trial (not to exceed 12 days) will be held between September 8 and 23, 2022. ORDERED by Judge Leonard P. Stark on 8/25/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl)
August 24, 2020 Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 8/24/2020. (Court Reporter B. Gaffigan.) Associated Cases: 1:19-cv-01979-LPS et al. (ntl)
August 20, 2020 Opinion or Order SO ORDERED, re (61 in 1:19-cv-02053-LPS, 69 in 1:20-md-02930-LPS, 63 in 1:20-cv-00445-LPS, 19 in 1:20-cv-00074-LPS, 112 in 1:19-cv-01979-LPS, 21 in 1:20-cv-00415-LPS, 33 in 1:19-cv-02021-LPS) STIPULATION TO EXTEND TIME for parties to submit a proposed scheduling order, proposed protective order, and letters regarding the disputed provisions to August 18, 2020 at 12:00 p.m. EST filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 8/20/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl)
August 19, 2020 Filing 74 REDACTED VERSION of (108 in 1:19-cv-01979-LPS, 65 in 1:20-md-02930-LPS) Statement Response to Notice of Supplemental Authority by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve)
August 18, 2020 Filing 73 REDACTED VERSION of (107 in 1:19-cv-01979-LPS, 64 in 1:20-md-02930-LPS) Notice (Other) of Supplemental Authority by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
August 18, 2020 Filing 72 NOTICE OF SERVICE of 1) Defendants Laurus Labs Ltd. and Laurus Generics Inc.'s Rule 26(a)(1) Initial Disclosures, and 2) Defendants Laurus Labs Ltd. and Laurus Generics Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Laurus Generics Inc., Laurus Labs Limited.(Swadley, Beth)
August 18, 2020 Filing 71 Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Disputed Provisions of Proposed Protective Order. (Attachments: #1 Exhibit 1-2, #2 Text of Proposed Order [Reflecting Parties' Disagreements])(Silver, Daniel)
August 18, 2020 Filing 70 Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Regarding Disputed Provisions of Proposed Scheduling Order. (Attachments: #1 Exhibit A-K, #2 Text of Proposed Order [Reflecting Parties' Disagreements])(Silver, Daniel)
August 17, 2020 Filing 69 STIPULATION TO EXTEND TIME for parties to submit a proposed scheduling order, proposed protective order, and letters regarding the disputed provisions to August 18, 2020 at 12:00 p.m. EST - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
August 14, 2020 Filing 68 NOTICE OF SERVICE of Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery of Defendant Nanjing Noratech Pharmaceutical Co. Limited filed by Nanjing Noratech Pharmaceutical Co., Limited.(Haney, Megan)
August 14, 2020 Opinion or Order SO ORDERED, re (110 in 1:19-cv-01979-LPS, 67 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Don J. Mizerk filed by Nanjing Noratech Pharmaceutical Co., Limited. Signed by Judge Leonard P. Stark on 8/14/20. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS (ntl)
August 13, 2020 Filing 67 MOTION for Pro Hac Vice Appearance of Attorney Don J. Mizerk - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: #1 Mizerk Pro Hac Certification)(Haney, Megan)
August 13, 2020 Pro Hac Vice Attorney Christopher B. Ferenc for Biocon Limited,for Biocon Pharma Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS (myr)
August 13, 2020 Opinion or Order SO ORDERED, re (109 in 1:19-cv-01979-LPS, 66 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Christopher B. Ferenc and Attorney Jillian M. Schurr filed by Biocon Limited, Biocon Pharma, Inc., Biocon Pharma Limited. Signed by Judge Leonard P. Stark on 8/13/20. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
August 13, 2020 Pro Hac Vice Attorney Jillian M. Schurr for Biocon Limited, for Biocon Pharma Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS) (myr)
August 12, 2020 Filing 66 MOTION for Pro Hac Vice Appearance of Attorney Christopher B. Ferenc and Attorney Jillian M. Schurr - filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Dorsney, Kenneth)
August 12, 2020 Filing 65 [SEALED] STATEMENT re (107 in 1:19-cv-01979-LPS, 64 in 1:20-md-02930-LPS) Notice (Other) Response to Notice of Supplemental Authority by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve)
August 11, 2020 Filing 64 [SEALED] NOTICE of Supplemental Authority by Novartis Pharmaceuticals Corporation (Attachments: #1 Decision, #2 Certificate of Service)(Silver, Daniel)
July 31, 2020 Filing 63 NOTICE OF SERVICE of MSN Laboratories Private Limiteds and MSN Pharmaceuticals Inc.s Initial Rule 26(a)(1) Disclosures; and MSN Laboratories Private Limiteds and MSN Pharmaceuticals Inc.s Initial ESI Disclosures filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios)
July 29, 2020 Opinion or Order Filing 62 ORAL ORDER: IT IS HEREBY ORDERED that a Scheduling and Discovery Telephone Conference is set for August 24, 2020 at 9:30 AM. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. The parties shall confer and submit a proposed schedule, proposed protective order, and letter(s) regarding the disputed provisions, all by no later than August 17. ORDERED by Judge Leonard P. Stark on 7/29/20. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00445-LPS (ntl)
July 27, 2020 Filing 61 NOTICE OF SERVICE of (1) Plaintiffs Rule 26(A)(1) Initial Disclosures; (2) Plaintiffs Initial Paragraph 3 Disclosures Regarding Electronic Systems Information; and (3) Plaintiffs Identification of Asserted patents and Accused Products pursuant to Paragraph 4(a) of the Delaware Default Standard for Discovery filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
July 27, 2020 Filing 60 NOTICE OF SERVICE of (1) Aurobindo's Rule 26(a)(1) Initial Disclosures; and (2) Aurobindo's Paragraph 3 Disclosures filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth)
July 27, 2020 Filing 59 NOTICE OF SERVICE of 1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limiteds Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; and 2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limiteds Fed. R. Civ. P. 26(a)(1) Initial Disclosures filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth)
July 22, 2020 Filing 58 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esq. regarding Scheduling Conference. (Gattuso, Dominick)
July 14, 2020 Filing 57 NOTICE OF SERVICE of 1) Novugen Pharma (Malaysia) Sdn. Bhd.s Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; and 2) Novugen Pharma (Malaysia) Sdn. Bhd.s Fed. R. Civ. P. 26(a)(1) Initial Disclosures filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth)
July 10, 2020 Filing 56 NOTICE OF SERVICE of Initial Disclosures and Core Technical Documents filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Rychlicki, Helena)
July 8, 2020 Filing 55 NOTICE OF SERVICE of Rule 26(a) Initial Disclosures and Paragraph 3 Disclosures filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc..(Ormerod, Eve)
July 8, 2020 Filing 54 NOTICE OF SERVICE of Rule 26(a) Initial Disclosures and Paragraph 3 Disclosures filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd..(Ormerod, Eve)
July 8, 2020 Filing 53 NOTICE OF SERVICE of Aurobindo's ANDA production filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth)
July 6, 2020 Filing 52 NOTICE OF SERVICE of Core Technical Documents filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios)
July 6, 2020 Filing 51 NOTICE OF SERVICE of Alkem's core technical documents filed by Alkem Laboratories Ltd..(Dorsney, Kenneth)
July 6, 2020 Filing 50 NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Core Technical Documents [Highly Confidential-Outside Attorney's Eyes Only] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
July 6, 2020 Filing 49 NOTICE OF SERVICE of Core Technical Document Production filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc..(Ormerod, Eve)
July 6, 2020 Filing 48 NOTICE OF SERVICE of Core Technical Document Production filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd..(Ormerod, Eve)
July 6, 2020 Filing 47 REDACTED VERSION of (42 in 1:20-md-02930-LPS) Reply Brief, (93 in 1:19-cv-01979-LPS) Reply Brief, in Further Support of Their Rule 12(c) Motion of Noninfringement of the '938 and '134 Patents by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.. (Attachments: #1 Exhibits 4-6)(Ormerod, Eve)
July 6, 2020 Filing 46 NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.s production of documents labeled CRYSAVA011315-CRYSAVA013121 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
July 6, 2020 Filing 45 NOTICE OF SERVICE of Core Technical Documents filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Ewing, Alexandra)
July 6, 2020 Filing 44 NOTICE OF SERVICE of Biocon's Production of ANDA filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Dorsney, Kenneth)
June 26, 2020 Filing 43 NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Core Technical Documents filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Poff, Adam)
June 26, 2020 Filing 42 [SEALED] REPLY BRIEF re #20 MOTION for Judgment on the Pleadings of Noninfringement of the '938 and '134 Patents filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Attachments: #1 Exhibits 4-6)(Ormerod, Eve) (Main Document 42 replaced on 6/26/2020) (ntl). (Attachment 1 replaced on 6/26/2020) (ntl).
June 26, 2020 Filing 41 NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Rule 26(a)(1)(A) Initial Disclosures filed by Nanjing Noratech Pharmaceutical Co., Limited.(Haney, Megan)
June 26, 2020 CORRECTING ENTRY: Corrected documents added to D.I. 93 in 19cv1979 and D.I. 42 in 20md2930 per request of counsel. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
June 13, 2020 Filing 40 NOTICE OF SERVICE of Discovery Disclosures Pursuant to the District of Delawares Default Standard and Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios)
June 12, 2020 Filing 39 NOTICE OF SERVICE of (1) Defendants Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and (2) Defendants Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc..(Cottrell, Frederick)
June 12, 2020 Filing 38 NOTICE OF SERVICE of (1) Paragraph 3 Disclosures and (2) Rule 26(a) disclosures filed by Alkem Laboratories Ltd..(Dorsney, Kenneth)
June 11, 2020 Filing 37 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Initial Disclosures Pursuant To Rule 26(A)(1) And Paragraph 3 Of The Delaware Default Standard For Discovery filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu)
June 11, 2020 Filing 36 NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.s Initial Disclosure Statement Pursuant to Fed. R. Civ. P. 26(A) and Paragraph 3 of the Delaware Default Standard for Discovery, Including Electronically Stored Information filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
June 11, 2020 Filing 35 NOTICE OF SERVICE of Biocon's Rule 26(a) and Paragraph 3 Disclosures filed by Biocon Limited, Biocon Pharma Limited.(Dorsney, Kenneth)
June 11, 2020 Filing 34 REDACTED VERSION of (84 in 1:19-cv-01979-LPS) Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
June 11, 2020 Filing 33 REDACTED VERSION of (83 in 1:19-cv-01979-LPS) Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
June 8, 2020 Filing 32 REDACTED VERSION of (79 in 1:19-cv-01979-LPS) Opening Brief in Support, (21 in 1:20-md-02930-LPS) Opening Brief in Support, Motion for Judgment on the Pleadings of Noninfringement of the '938 and '134 Patents by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.. (Attachments: #1 Exhibits 1-3)(Ormerod, Eve)
June 4, 2020 Filing 31 [SEALED] DECLARATION re (83 in 1:19-cv-01979-LPS) Answering Brief in Opposition, (30 in 1:20-md-02930-LPS) Answering Brief in Opposition, of Jared L. Stringham by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-8, #2 Certificate of Service)(Silver, Daniel)
June 4, 2020 Filing 30 [SEALED] ANSWERING BRIEF in Opposition re #20 MOTION for Judgment on the Pleadings of Noninfringement of the '938 and '134 Patents filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 6/11/2020. (Attachments: #1 Certificate of Service)(Silver, Daniel)
June 1, 2020 Opinion or Order SO ORDERED, re (29 in 1:20-md-02930-LPS, 58 in 1:20-cv-00445-LPS) MOTION for Pro Hac Vice Appearance of Attorney Tasneem A. Dharamsi of Parker Poe & Bernstein LLP filed by Mylan Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 6/1/20. Associated Cases: 1:20-cv-00445-LPS, 1:20-md-02930-LPS (ntl)
May 29, 2020 Filing 29 MOTION for Pro Hac Vice Appearance of Attorney Tasneem A. Dharamsi of Parker Poe & Bernstein LLP - filed by Mylan Pharmaceuticals Inc.. (Palapura, Bindu)
May 21, 2020 Filing 28 NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.s documents bearing Bates numbers CRYSAVA000001 - CRYSAVA011314 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick)
May 15, 2020 Opinion or Order SO ORDERED, re (27 in 1:20-md-02930-LPS, 81 in 1:19-cv-01979-LPS) STIPULATION TO EXTEND TIME Briefing regarding Torrent's Motion for Judgment on the Pleadings of Noninfringement of the '938 and '134 Patents to See Stip for details filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 5/13/20. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
May 11, 2020 Filing 27 STIPULATION TO EXTEND TIME Briefing regarding Torrent's Motion for Judgment on the Pleadings of Noninfringement of the '938 and '134 Patents to See Stip for details - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
May 8, 2020 Filing 26 NOTICE of Supplemental Authority by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd. re (78 in 1:19-cv-01979-LPS) MOTION for Judgment on the Pleadings of Noninfringement of the '938 and '134 Patents, (20 in 1:20-md-02930-LPS) MOTION for Judgment on the Pleadings of Noninfringement of the '938 and '134 Patents (Attachments: #1 Exhibit A)(Ormerod, Eve)
May 7, 2020 Pro Hac Vice Attorney Stuart D. Sender for Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
May 7, 2020 Opinion or Order SO ORDERED, re #25 MOTION for Pro Hac Vice Appearance of Attorney Amit Singhai filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., #23 MOTION for Pro Hac Vice Appearance of Attorney Stuart D. Sender filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., #24 MOTION for Pro Hac Vice Appearance of Attorney Frank D. Rodriguez filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 5/7/20. (ntl)
May 6, 2020 Filing 25 MOTION for Pro Hac Vice Appearance of Attorney Amit Singhai - filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Attachments: #1 Certificate of Service to Motion and Order for Admission Pro Hac Vice)(Rychlicki, Helena)
May 6, 2020 Filing 24 MOTION for Pro Hac Vice Appearance of Attorney Frank D. Rodriguez - filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Attachments: #1 Certificate of Service to Motion and Order for Admission Pro Hac Vice)(Rychlicki, Helena)
May 6, 2020 Filing 23 MOTION for Pro Hac Vice Appearance of Attorney Stuart D. Sender - filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Attachments: #1 Certificate of Service to Motion and Order for Admission Pro Hac Vice)(Rychlicki, Helena)
May 6, 2020 Filing 22 NOTICE of Appearance by Helena C. Rychlicki on behalf of Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Rychlicki, Helena)
May 6, 2020 Pro Hac Vice Attorney Stephen R. Auten for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS(kmd)
May 5, 2020 Pro Hac Vice Attorney Alan B. Clement, Zhibin Li, and Peter J. Fallon for Novugen Pharma (Malaysia) Sdn. Bhd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-02053-LPS(sam)
May 4, 2020 Filing 21 [SEALED] OPENING BRIEF in Support re #20 MOTION for Judgment on the Pleadings of Noninfringement of the '938 and '134 Patents filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..Answering Brief/Response due date per Local Rules is 5/18/2020. (Attachments: #1 Exhibits 1-3)(Ormerod, Eve)
May 4, 2020 Filing 20 MOTION for Judgment on the Pleadings of Noninfringement of the '938 and '134 Patents - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Attachments: #1 Text of Proposed Order)(Ormerod, Eve)
April 28, 2020 Filing 19 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin, Ltd. for Lupin Atlantis Holdings, S.A.; Corporate Parent Nanomi B.V. for Lupin Inc. filed by Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc.. (Cottrell, Frederick)
April 21, 2020 Pro Hac Vice Attorney Edward D. Pergament for Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS(sam)
April 21, 2020 Pro Hac Vice Attorney Roshan P. Shrestha for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
April 20, 2020 Filing 18 MOTION for Pro Hac Vice Appearance of Attorney Alan B. Clement, Peter J. Fallon and Zhibin Li - filed by Novugen Pharma (Malaysia) Sdn. Bhd.. (Swadley, Beth)
April 20, 2020 Opinion or Order SO ORDERED, re (18 in 1:20-md-02930-LPS, 50 in 1:19-cv-02053-LPS) MOTION for Pro Hac Vice Appearance of Attorney Alan B. Clement, Peter J. Fallon and Zhibin Li filed by Novugen Pharma (Malaysia) Sdn. Bhd. Signed by Judge Leonard P. Stark on 4/20/20. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
April 15, 2020 Opinion or Order SO ORDERED, re (11 in 1:20-md-02930-LPS, 75 in 1:19-cv-01979-LPS) STIPULATION of Dismissal of Defendant Lupin's Seventh, Eighth, and Ninth Counterlaims without Prejudice filed by Lupin Limited, Lupin Atlantis Holdings, S.A. Signed by Judge Leonard P. Stark on 4/13/20. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
April 14, 2020 Filing 17 NOTICE of Appearance by Eve H. Ormerod on behalf of Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. (Ormerod, Eve)
April 14, 2020 Pro Hac Vice Attorney Edward D. Pergament for Torrent Pharma Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS(amf)
April 13, 2020 Filing 16 NOTICE of Appearance by Dominick T. Gattuso on behalf of Crystal Pharmaceutical (Suzhou) Co., Ltd. (Gattuso, Dominick)
April 13, 2020 Filing 15 NOTICE of Appearance by Alexandra M. Joyce on behalf of Novartis Pharmaceuticals Corporation (Joyce, Alexandra)
April 13, 2020 Filing 14 NOTICE of Appearance by Daniel M. Silver on behalf of Novartis Pharmaceuticals Corporation (Silver, Daniel)
April 9, 2020 Filing 13 MOTION for Pro Hac Vice Appearance of Attorney Edward D. Pergament - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve)
April 9, 2020 Filing 12 MOTION for Pro Hac Vice Appearance of Attorney Edward D. Pergament - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc.. (Ormerod, Eve)
April 9, 2020 Opinion or Order SO ORDERED, re (49 in 1:19-cv-02053-LPS, 12 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Edward D. Pergament filed by Hetero USA Inc.,, Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III. Signed by Judge Leonard P. Stark on 4/9/20. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
April 9, 2020 Opinion or Order SO ORDERED, re (76 in 1:19-cv-01979-LPS, 13 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Edward D. Pergament filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. Signed by Judge Leonard P. Stark on 4/9/20. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
April 6, 2020 Filing 11 STIPULATION of Dismissal of Defendant Lupin's Seventh, Eighth, and Ninth Counterlaims without Prejudice by Lupin Atlantis Holdings, S.A., Lupin Limited. (Cottrell, Frederick)
April 3, 2020 Pro Hac Vice Attorney Kenneth S. Canfield for Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lak)
April 2, 2020 Filing 10 STATEMENT Plaintiff's Answer to Mylan Pharmaceuticals Inc.'s Counterclaims by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
April 2, 2020 Filing 9 MOTION for Pro Hac Vice Appearance of Attorney Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certifications for Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham)(Silver, Daniel)
April 2, 2020 Opinion or Order SO ORDERED, re (74 in 1:19-cv-01979-LPS, 6 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Kenneth S. Canfield filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. Signed by Judge Leonard P. Stark on 4/2/20. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
April 2, 2020 Opinion or Order SO ORDERED, re (8 in 1:20-md-02930-LPS, 48 in 1:19-cv-02053-LPS) MOTION for Pro Hac Vice Appearance of Attorney Kenneth S. Canfield filed by Hetero USA Inc.,, Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III. Signed by Judge Leonard P. Stark on 4/2/20. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl)
April 2, 2020 Opinion or Order SO ORDERED, re (56 in 1:20-cv-00445-LPS, 9 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 4/2/20. Associated Cases: 1:20-cv-00445-LPS, 1:20-md-02930-LPS (ntl)
April 1, 2020 Filing 8 MOTION for Pro Hac Vice Appearance of Attorney Kenneth S. Canfield - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc.. (Ormerod, Eve)
April 1, 2020 Filing 7 NOTICE of Appearance by Tracey E. Timlin on behalf of Mylan Pharmaceuticals Inc. (Timlin, Tracey)
April 1, 2020 Filing 6 MOTION for Pro Hac Vice Appearance of Attorney Kenneth S. Canfield - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve)
April 1, 2020 Filing 5 NOTICE of Appearance by Bindu Ann George Palapura on behalf of Mylan Pharmaceuticals Inc. (Palapura, Bindu)
April 1, 2020 Filing 4 NOTICE of Appearance by David Ellis Moore on behalf of Mylan Pharmaceuticals Inc. (Moore, David)
March 31, 2020 Filing 3 MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Auten and Attorney Roshan P. Shrestha - filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth)
March 31, 2020 CORRECTING ENTRY: Case from West VA was inadvertently opened as 20-MD-445. The proper case number is 20-CV-445. Associated Cases: 1:20-cv-00445-LPS et al.(rwc)
March 31, 2020 Opinion or Order SO ORDERED, re (3 in 1:20-md-02930-LPS, 73 in 1:19-cv-01979-LPS) MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Auten and Attorney Roshan P. Shrestha filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 3/31/20. Associated Cases: 1:19-cv-01979-LPS, 1:20-md-02930-LPS (ntl)
March 30, 2020 Filing 2 NOTICE TO COUNSEL: MDL No. 1:20-md-2930 has been opened and assigned to the Honorable Leonard P. Stark. Attorneys of record who will be electronically filing documents may use the attached form to register for a CM/ECF login and password or they may continue to go through their Local Counsel. Please see the docket for further entries. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS(rwc)
March 30, 2020 Filing 1 CERTIFIED TRANSFER ORDER re: 20-MD-2930 - signed 3/27/20 by Clerk, MDL Panel. (rwc)
March 27, 2020 Remark: The following cases in the District of Delaware are included in this MDL: CA 19-1979-LPS, CA 19-2021-LPS, CA 19-2053-LPS. (rwc)
March 27, 2020 NOTICE: Documents relating to all actions should be filed on the master docket sheet (20-MD-2930) AND on the docket sheet of each individual action. Documents relating to two or more, but not all, individual actions should be filed on the master docket sheet, and on the docket sheet of each affected individual action. Documents affecting a single individual action should be filed on the docket sheet of that action and on the master docket sheet. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS(rwc)

Access additional case information on PACER

Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.

Access this case on the Delaware District Court's Electronic Court Filings (ECF) System

Search for this case: In re: Entresto (Sacubitril/Valsartan) Patent Litigation
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Web [ Unicourt | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Biocon Pharma Limited
Represented By: Kenneth Laurence Dorsney
Represented By: Matthew M. Holub
Represented By: Jitendra Malik
Represented By: Christopher B. Ferenc
Represented By: Jillian M. Schurr
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Teva Pharmaceuticals USA, Inc.
Represented By: Karen Elizabeth Keller
Represented By: Leora Ben-Ami
Represented By: Mira Mulvaney
Represented By: Mark C. McLennan
Represented By: Nathan Roger Hoeschen
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Alkem Laboratories Ltd.
Represented By: Kenneth Laurence Dorsney
Represented By: Roshan P. Shrestha
Represented By: Stephen R. Auten
Represented By: Jane S. Berman
Represented By: Philip Y. Kouyoumdjian
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Lupin Inc.
Represented By: Andrea L. Cheek
Represented By: Alexandra M. Ewing
Represented By: William R. Zimmerman
Represented By: Frederick L. Cottrell, III
Represented By: Carol M. Pitzel Cruz
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Macleods Pharmaceuticals Ltd.
Represented By: John M. Seaman
Represented By: Corey Weinstein
Represented By: April M. Kirby
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Dr. Reddy's Laboratories, Inc.
Represented By: Christopher D. Jones
Represented By: Stamatios Stamoulis
Represented By: Bryan D. Beel
Represented By: Autumn N. Nero
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Crystal Pharmaceutical (Suzhou) Co., Ltd.
Represented By: Elizabeth M. Crompton
Represented By: C. Kyle Musgrove
Represented By: Dominick T. Gattuso
Represented By: Scott A. Cunning, II
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Lupin Atlantis Holdings, S.A.
Represented By: Andrea L. Cheek
Represented By: Alexandra M. Ewing
Represented By: William R. Zimmerman
Represented By: Frederick L. Cottrell, III
Represented By: Carol M. Pitzel Cruz
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Alembic Pharmaceuticals Limited
Represented By: Helena C. Rychlicki
Represented By: Amit Singhai
Represented By: Frank D. Rodriguez
Represented By: Stuart D. Sender
Represented By: Eve H. Ormerod
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Macleods Pharma USA, Inc.
Represented By: John M. Seaman
Represented By: Corey Weinstein
Represented By: April M. Kirby
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Laurus Labs Limited
Represented By: Adam Wyatt Poff
Represented By: Dennies Varughese, Pharm.D.
Represented By: Nirav N. Desai
Represented By: Joseph H. Kim
Represented By: Dennies Varughese, Pharm.D
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Aurobindo Pharma USA Inc.
Represented By: Kenneth Laurence Dorsney
Represented By: James E. Nealon
Represented By: Steven J. Moore
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Lupin Pharmaceuticals, Inc.
Represented By: Andrea L. Cheek
Represented By: Alexandra M. Ewing
Represented By: William R. Zimmerman
Represented By: Frederick L. Cottrell, III
Represented By: Carol M. Pitzel Cruz
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Dr. Reddys Laboratories, Ltd.
Represented By: Christopher D. Jones
Represented By: Stamatios Stamoulis
Represented By: Bryan D. Beel
Represented By: Autumn N. Nero
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter claimant: Biocon Limited
Represented By: Kenneth Laurence Dorsney
Represented By: Matthew M. Holub
Represented By: Jitendra Malik
Represented By: Christopher B. Ferenc
Represented By: Jillian M. Schurr
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Hetero USA Inc.,
Represented By: Eve H. Ormerod
Represented By: Neal C. Belgam
Represented By: Dmitry V. Shelhoff
Represented By: Kenneth S. Canfield
Represented By: Edward D. Pergament
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Torrent Pharma Inc.
Represented By: Eve H. Ormerod
Represented By: Neal C. Belgam
Represented By: Dmitry V. Shelhoff
Represented By: Kenneth S. Canfield
Represented By: Edward D. Pergament
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Zydus Pharmaceuticals (USA) Inc.
Represented By: Adam Wyatt Poff
Represented By: James T. Peterka
Represented By: Michael J. Gaertner
Represented By: Nina Vachhani
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Torrent Pharmaceuticals Ltd.
Represented By: Eve H. Ormerod
Represented By: Neal C. Belgam
Represented By: Dmitry V. Shelhoff
Represented By: Kenneth S. Canfield
Represented By: Edward D. Pergament
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Novugen Pharma (Malaysia) Sdn. Bhd.
Represented By: Adam Wyatt Poff
Represented By: Zhibin Li
Represented By: Peter J. Fallon
Represented By: Alan B. Clement
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Hetero Labs Limited Unit III
Represented By: Eve H. Ormerod
Represented By: Neal C. Belgam
Represented By: Dmitry V. Shelhoff
Represented By: Kenneth S. Canfield
Represented By: Edward D. Pergament
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Nanjing Noratech Pharmaceutical Co., Limited
Represented By: John C. Phillips, Jr.
Represented By: Megan C. Haney
Represented By: Masha Femi
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Laurus Generics Inc.
Represented By: Adam Wyatt Poff
Represented By: Dennies Varughese, Pharm.D.
Represented By: Nirav N. Desai
Represented By: Joseph H. Kim
Represented By: Dennies Varughese, Pharm.D
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: MSN Laboratories Private Limited
Represented By: Stamatios Stamoulis
Represented By: Richard Juang
Represented By: Ronald M. Daignault
Represented By: Richard Charles Weinblatt
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: MSN Life Sciences Private Limited
Represented By: Stamatios Stamoulis
Represented By: Richard Charles Weinblatt
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Lupin Limited
Represented By: Andrea L. Cheek
Represented By: Alexandra M. Ewing
Represented By: William R. Zimmerman
Represented By: Frederick L. Cottrell, III
Represented By: Carol M. Pitzel Cruz
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: MSN Pharmaceuticals Inc.
Represented By: Stamatios Stamoulis
Represented By: Richard Juang
Represented By: Ronald M. Daignault
Represented By: Richard Charles Weinblatt
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Alembic Pharmaceuticals, Inc.
Represented By: Helena C. Rychlicki
Represented By: Amit Singhai
Represented By: Frank D. Rodriguez
Represented By: Stuart D. Sender
Represented By: Eve H. Ormerod
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Hetero Labs Limited
Represented By: Eve H. Ormerod
Represented By: Neal C. Belgam
Represented By: Dmitry V. Shelhoff
Represented By: Kenneth S. Canfield
Represented By: Edward D. Pergament
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Cadila Healthcare Ltd.
Represented By: Adam Wyatt Poff
Represented By: Beth Ann Swadley
Represented By: James T. Peterka
Represented By: Michael J. Gaertner
Represented By: Nina Vachhani
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Clerk of MDL Panel
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Not classified by court: Mylan Pharmaceuticals Inc.
Represented By: Gordon H. Copland
Represented By: Bindu Ann George Palapura
Represented By: Karen L. Carroll
Represented By: David Ellis Moore
Represented By: Micheal L. Binns
Represented By: Tracey E. Timlin
Represented By: William J O'Brien
Represented By: Robert L. Florence
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
In re: Entresto (Sacubitril/Valsartan) Patent Litigation
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Counter defendant: Novartis Pharmaceuticals Corporation
Represented By: Christina Schwarz
Represented By: Jared L. Stringham
Represented By: Daniel M. Silver
Represented By: Alexandra M. Joyce
Represented By: Nicholas N. Kallas
Represented By: Shannon K. Clark
Represented By: Sandra K. Law
Represented By: Laura K. Fishwick
Represented By: Susanne L. Flanders
Represented By: Gregory J. Manas
Represented By: James F. Companion
Represented By: Christopher E. Loh
Represented By: Jared Stringham
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Defendant: Noratech Labs, Inc.
Represented By: Megan C. Haney
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.

Why Is My Information Online?